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ABSTRACT
FUNCTIONALIZED NANOPARTICLES FOR
AMF-INDUCED GENE AND DRUG DELIVERY
12th

November, 2011

SOUVIK BISWAS
The properties and broad applications of nano-magnetic colloids have
generated much interest in recent years. Specially, Fe304 nanoparticles have attracted
a great deal of attention since their magnetic properties can be used for hyperthermia
treatment or drug targeting.

For example, enhanced levels of intracellular gene

delivery can be achieved using Fe304 nano-vectors in the presence of an external
magnetic field, a process known as 'magnetofection'. The low cytotoxicity, tunable
particle size, ease of surface functionalization, and ability to generate thermal energy
using an external alternating magnetic field (AMF) are properties have propelled
Fe304 research to the forefront ofnanoparticle research.
The strategy of nanoparticle-mediated, AMF-induced heat generation has
been used to effect intracellular hyperthermia. One application of this 'magnetic
hyperthermia' is heat activated local delivery of a therapeutic effector (e.g.; drug or
polynucleotide). This thesis describes the development of a magnetic nano-vector for
AMF-induced, heat-activated pDNA and small molecule delivery.

VB

The use of heat-inducible vectors, such as heat shock protein (hsp) genes, is a
promising mode of gene therapy that would restrict gene expression to a local region
by focusing a heat stimulus only at a target region. We thus aimed to design an Fe304
nanoparticle-mediated gene transfer vehicle for AMF-induced localized gene
expression. We opted to use 'click' oximation techniques to assemble the magnetic
gene transfer vector.

Chapter 2 describes the synthesis, characterization, and

transfection studies of the oxime ether lipid-based nano-magnetic vectors MLP and
dMLP.

The synthesis and characterization of a novel series of quaternary

ammonium aminooxy reagents (2.1-2.4) is described.

These cationic aminooxy

compounds were loaded onto nanoparticles for ligation with carbonyl groups and also
to impart a net positive charge on the nanoparticle surface. Our studies indicated that
the non-toxic magnetoplexes (magnetic nanoparticle + pDNA complex) derived from
dMLP deliver pDNA into mammalian cells even without external magnetic

assistance. To date, dMLP is the only polymer-free magnetic gene delivery system
that can deliver pDNA without any magnetic assistance.
Chapter 3 of this thesis outlines the synthesis and characterization of other
oxime ether lipids and details studies using derived-lipoplexes. These lipids were
evaluated in pDNA and siRNA transfection studies in various mammalian cell lines.
This work constitutes the first use of an oxime ether as the linking domain in cationic
transfection lipids. These biocompatible oxime ether lipids can be readily assembled
by click chemistry through ligation of hydrophobic aldehydes with quaternary
ammonium aminooxy salts.

Our studies showed that the oxime ether lipids

Vlll

transfected pDNA and siRNA efficiently in MCF -7, H 1792, and in PAR C 10 cells
comparable to and in some cases better than commercial transfection lipids.
Chapter 4 describes the design and characterization of a nano-magnetic
delivery system for AMF-induced drug (doxorubicin) release. In efforts to develop a
magnetic formulation free from thermo sensitive materials, such as hydrogels, we
synthesized three nanoparticle-based doxorubicin formulations

using charge

interactions as the key associative force. To do so, we synthesized and characterized
a novel cationic oxime ether conjugate at C-13 of doxorubicin. Our investigation
indicated that the positive charge of the oxime ether drug conjugate tended to bind
better to the negatively charged nanoparticle than did the other formulations prepared
in stepwise manner.

Our findings show that the nano-magnetic formulations

remained essestially inactive at body temperature (37.5 °C) and released a majority of
the cargo only when exposed to an external AMF.

Our designed magnetic drug

delivery platform is the first example of an AMF-inducible system that does not
depend on the inclusion of thermo sensitive materials.
Finally, we have developed a bioanalytical application of the highly
chemoselective oximation chemistry using aminooxy reagent 2.1.

Chapter 5

describes a silica microchip containing micropillars coated with cationic aminooxy
reagent 2.1. The microchip captures gaseous ketones and aldehydes from exhaled
human breath. A brief description of microchip fabricated breath analyzer and breath
analysis is described in Chapter 5.

Our studies showed that the acetone capture

efficiency of the aminooxy-Ioaded microchip was 98%.
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CHAPTER!

MAGNETIC NANOPARTICLES FOR DRUG DELIVERY

1.1. Introduction
1.2. Magnetic Vectors for Polynucleotide Delivery
1.3. Magnetic Hyperthermia-Induced Drug Delivery

1

1.1 Introduction

The recent and widespread development of nanoscale technologies is
beginning to change the foundations of disease diagnosis, treatment, and prevention.
These technological innovations can be grouped into a new field known as
nanomedicine, and this field can be defined as an offshoot of nanotechnology
featuring highly specific medical interventions at the molecular scale for curing
disease or repairing damaged tissues, such as bone, muscle, or nerve" (National
Institute of Health, Bethesda, MD).l

Nanomedicine thus covers a large

interdisciplinary scientific research area. This includes nanoparticles that have been
engineered as bio-mimics (e.g., functionalized carbon nanotubes), nanomachines
(e.g., those made from interchangeable DNA parts and DNA scaffolds),
nanoconstructs as biomaterials (e.g., nanofibers of peptides and peptide amphiphiles
for tissue engineering), and nanoscale microfabrication-based devices (e.g., silicon
microchips for drug release and disease analysis).2 Furthermore, there is a huge array
of intriguing nanoparticulate-based platforms that is capable of delivering genetic
materials (pDNA, siRNA), drugs, or diagnostic agents to the desired site of therapy.
Among these nano-entities, inorganic nanoparticle-based delivery systems have
emerged as an attractive field of research in recent years. Inorganic nanoparticles
have two key advantages as a delivery system: ease of preparation with defined size,
and they can serve as multifunctional carriers by attaching, for example, both reactive
and contrast elements. 3
Inorganic nanomaterials generally include gold nanoparticles, magnetic
nanoparticles (mainly Fe304 and yFe203), silica nanoparticles and various quantum

2

dots (QD). Magnetic iron oxide nanoparticles, especially magnetite or Fe304 and
maghemite or y-Fe203 (y-phase defined by a cubic crystal structure) show great
potential in biomedical research.

In addition to being non-toxic,4,

5

flexibly

functionalized and colloidally stable under physiological conditions, iron oxide
nanoparticles can be magnetized at the nanoscale range by an external magnetic field.
This facilitates their purification and also assists in magnetic targeting of the carriers
to the desired site of therapy.6 These properties make iron oxide nanoparticle
formulations promising candidates for gene and drug delivery applications.
Magnetic nanoparticles generate thermal energy when induced with an
alternating magnetic field (AMF) through the magnetic oscillation of their magnetic
moments. This is due to what is known as Neel and Brownian relaxation (detailed
discussion in section IC). The heat generated in this manner has been effectively
used for non-invasive, hyperthermia-based tumor therapy? Iron oxide nanoparticles
also can be used as Tr weighted8 magnetic resonance imaging contrast agents. In fact,
the commercial formulation Feridex I.V.TM was approved for used as an MRI contrast
agent in humans.

However, for unknown reasons this formulation was been

discontinued by the manufacturer (AMAG Pharmaceuticals, Lexington, MA) after
November 2008. Combidex™ (Advanced Magnetics, Inc., MA) is another iron oxide
nanoparticle-based formulation used as an MRI contrast agent. Combidex™ is now
in Phase III clinical trials. 9 The hyperthermic effects and the Trweighted magnetic
resonance imaging make iron oxide nanoparticles an ideal candidate for theranostic
(therapeutic + diagnostic) applications.

3

This dissertation will describe the present status of magnetic nanoparticlemediated gene and drug delivery and my efforts to improve the efficiencies of these
methods. Specially, my thesis research is aimed at developing an efficient magnetic
nanoparticle-mediated drug delivery system that can release its cargo in response to
the heat generated by an externally applied AMF stimulus.

1.2. Magnetic Vectors for Polynucleotide Delivery
Gene Therapy
According to the American Society of Gene Therapy, gene therapy can be
defined as the "use of genetic material to modify a patient's cells for the treatment of
an inherited or acquired disease." The therapy involves the introduction and uptake of
exogenous genetic material into a cell, with incorporation and expression of the gene
(i.e., transgene) in the nucleus to provide a desired therapeutic effect. For acquired
diseases like cancer, gene therapy uses genes to directly or indirectly cause the
demise of the cancerous cells. Various therapeutic effects have been realized with the
delivery of genes capable of inducing apoptosis, immunogenic responses against the
host cell, or inactivating oncogenes.
Despite the original promise, gene therapy remains very inefficient.

This

inefficiency of transfection (i.e., combined output of gene transfer and expression) is
directly related to the pathway via which DNA makes the journey from delivery to
nuclear translocation.

This mechanism is well studied. 10,

11

The ultimate fate of

exogenous DNA depends on the ability to overcome the barriers during the transgene
delivery, and these barriers include: (1) stability in the extracellular space, association

4

with plasma membrane, and importantly cellular internalization via endocytosis, (2)
intra-cellular trafficking including endosomal release, (3) cytosolic diffusion, and (4)
nuclear localization (Figure 1.1).

The driving force behind much gene therapy

research is to overcome these barriers. In comparison to most small molecule drugs,
nucleic acids have poor bioavailabilty due to the chemical composition of cell
membranes, which have a net anionic surface potential. 12 The anionic ribophosphate
backbone of DNA is electrostatically repulsed from the cellular surface. In addition,
the immune system may react to exogenous DNA or RNA, which will cause rapid
enzymatic degradation of the polynucleotide.

Therefore, for most gene therapy

applications, DNA must be delivered to the cell surface in a system that promotes
cellular internalization while also protecting the DNA from degradation. The ideal
vector must be able to condense DNA into discrete particles that protect the transgene
from degradation and provide sufficient delivery into the target cell and its nucleus.
The vector must be nontoxic, non-immunogenic and should be easy and inexpensive
to produce.

Presently there are three modes of gene delivery: uncomplexed

DNA/siRNA delivery or "naked" polynucleotide delivery, viral-mediated gene
delivery, and non-viral mediated gene delivery.

5

Endosome

/

Lysosome
Lysosomal
degradation

4

T"mse';ption

j

mRNA

Figure 1.1. Barriers to effective gene transfer: after aSSOcIatIOn with cellular
membrane, (1) endocytosis, (2) intracellular trafficking and endosomal escape, (3)
cytosolic diffusion and (4) translocation to the nucleus and access into the nucleus.
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Naked DNA (or siRNA) delivery

The simplest gene delivery strategy is injection/inhalation of 'naked'
(uncomplexed) nucleic acids (e.g. pDNA, siRNA).

This method has attracted

researchers due to its simplicity and lack of toxicity observed for naked pDNA.
Several pre-clinical and clinical trials have shown that this strategy is useful for
delivery of pDNA into skin, muscle, liver, lungs and into some solid tumors. 13,

14, 15

However, the direct injection of naked nucleic acids into tissue or blood is ineffective
and limited to a few tissues due to following reasons: first, nucleic acids generally
undergo rapid enzymatic degradation by nucleases in vivo. Secondly, naked nucleic
acids cannot reach many organs by systemic injection because the liver rapidly
sequesters them. Due to its relatively smaller size, kidneys clear siRNA rapidly.
Finally, the net negative charge of a cellular membrane may repel oligonucleotides or
pDNA and cause low efficiency of cellular uptake. To overcome these limitations, it
is necessary to develop gene delivery vectors to safely transport DNA/RNA into
targeted cells.
Viral vectors

Although my thesis research is focused on developing non-viral gene delivery
vectors, a brief discussion on viral-based gene delivery systems is necessary to
provide a better perspective of the field.

Viruses are nature's most effective

candidates to infect cells with genetic material. Once the immunological component
of a virus is dismantled, the viral machinery may be exploited. Likewise, removing
replication factors from the virus avoids the potential side effects due to non-targeted

7

distribution of the viral-vectors.

Manipulation of viruses and engineering viral

vectors have become maj or branch of gene therapy. 16
Retrovirus vectors (RV) are one of the most effective means for gene transfer.
Nusbaum et al. in 2000 demonstrated for the first time the proof of concept of
retroviral gene therapy by treating a genetic disease. 17 Adenovirus is also commonly
used for viral transduction and it is capable of infecting both dividing and quiescenet
cells. 18 Although viral vectors for gene transfer fulfill the requirement of efficient
gene transfer, virus mediated transduction suffers from drawbacks, such as like strong
immune responses,19 nonspecific transduction,20 limited polynucleotide carrying
capacity and high cost of production.2I , 22
Non-viral gene delivery

Non-viral gene delivery utilizes synthetic carriers to mimic viral transfection
without the associated side effects. Commonly used non-viral vectors are cationic
lipids (CL), polymers, and various inorganic nanomaterials.

Generally, non-viral

gene delivery vectors possess positive charge density on their surface to facilitate
binding to the negatively charged phosphates of the polynucleotide backbone (i.e.,
electrostatic attractions) to form a complex (Figure 1.2). The cationic liposomepolynucleotide complex is known as a lipoplex and the polymeric counterpart is
known polyplex (Figure 1.2).

8
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Figure 1.2. Cationic gene delivery systems: formulation of cationic lipid- and
polymer-based delivery systems.
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The advantages of low immunogenicity, the ability to transfect RNA or DNA
of nearly unlimited size,23, 24 and the relative ease of lipoplex (cationic lipid-plasmid
DNAIRNA complex) formulation continue to attract interest aimed at developing
safer and more efficient cationic lipids. Typically a cationic lipid, like 1,2-di-Ooctadecenyl-3-trimethylammonium

propane

(DOTMA)25

and

N-[1-(2,3-

dioleoyloxy)propyl]-N,N,N,-trimthylammonium chloride (DOTAPi 6 has a positively
charged head group for DNA/RNA binding connected to a dual chain hydrophobic
domain via functional linker (Figure 1.3). Cationic lipids are co-formulated with a

Polar
Domain Linker

Hydrophobic
Domain

CI-'~~O

/1

l

o

ether

DOTMA

o
CI-'N~O
/1
l

o

ester

0
DOTAP

Figure 1.3. Chemical structure of DOTMA and DOTAP.

neutral lipid or co-lipid, such as 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (or
DOPE), to form a cationic liposome (Figure 1.2). The liposome then condenses the
DNA/RNA spontaneously to form a lipoplex (Figure 1.2). The lipid bilayer prevents
the DNA/RNA from degradation by extracellular nuclease. Co-lipids can enhance
endosomal escape of DNA during transfection. 27 The polynucleotide to CL ratio for
lipoplex formulation must be separately optimized, but generally the lipoplexes are
formulated with an excess positive charge to provide better interaction with the cell

10

membrane.
Cationic polymer-based gene delivery vectors are also becoming very
promising in nonviral gene therapy research. Cationic polymers, e.g., poly-L-Iysine
(PLL),28 polyethylenimine (PEl), 29 polyamidoamine dendrimers (PMAM), 30 and
chitosan31 can bind with the polynucleotide backbone to form a polymer/DNA or
siRNA complex or a polyplex (Figure 1.2). In contrast to other polymers, PEl does
not require an endosomolytic agent due to its intrinsic endosomolytic property. This
ability to facilitate endosomal escape makes PEl superior to other transfection active
agents. The PEl backbone consists of repeating '-CH2CH2NH-' ethylenimine motifs
that provide excellent solubility. Roughly 20% of the nitrogens are protonated at
physiological pH. 32 PEl forms a dense polyplex.33 Due to its "proton sponge" effect,
polyplexes

derived

from

PEl

avoid

lysosomal

trafficking

and

enzymatic

degradation,34 and this usually results in better transfection than other polymers.
Although PEl is one of the best polymers for gene transfer, in vivo applications using
PEl suffer from toxicity. The high positive charge density of PEl disrupts the cellular
membrane. 35 Thus, complications arising from vector toxicity affect many PEl-based
gene therapy approaches. 36

Inorganic nanoparticle-based vectors for gene delivery
Inorganic

nanoparticles

are

becoming

very

popular

due

to

their

biocompatibility, simple method of synthesis, size controllability and ease of surface
functionalization for various biomedical applications. Inorganic nanoparticles can be
coated with biocompatible polymers, and linkers can be attached to their surface to
tether various entities (e.g., targeting elements) for different applications.

11

A

hydrophobic drug can be attached to these nanoparticles for delivery purpose and
simultaneous cell specific targeting can be achieved when these drug-loaded nanocarriers conjugated to a targeting moiety (e.g., peptides or antibodies, Figure 1.4).
Nanoparticles can behave like a multifunctional platform for theranostics when the
surface of the particle is further conjugated to a radionucleotide tracer for positron
emission tomography (PET imaging) or when linked to a fluorescent-active molecule
for bioimaging.

The magnetic nano core makes the nanoparticles MRI active.

Therapeutic agents, like hydrophilic drugs or nucleic acids, can also be encapsulated
into the hydrophilic coating shell (Figure 1.4).
For gene delivery purposes nucleic acids are mostly loaded onto gold
nanoparticles (GNP) through thiol linkages or electrostatic interaction with cationic
gold nanoparticles. 37, 38, 39,40 Elbakry et al. first developed the PEIIsiRNAIPEIAuNP
system to deliver siRNA into cells and knock down the expression of a target gene
based on the self-assembly layer-by-Iayer technology.36 Due to its high transfection
capacity, PEl coated mesoporous silica nanoparticles (PEI-MSNP) are very common
vectors for nucleic acid delivery to mammalian cells. 41 , 42, 43 In addition to their ability
to increase the plasmid concentration at the cell surface via sedimentation,44 the
mesopore structures provide the possibility to carry additional elements such as
drugs,45 magnetic tags,39 and chromophores (to monitor drug delivery or the
intracellular trafficking of nanoparticles).46 Simple DNA coated calcium phosphate
nanoparticles (CaP),47, 48 bisphosphonate stabilized CaP49 and cationic lipid coated
CaPs 50 have been used for cellular delivery of exogenous DNA. Ca2+ ion plays an
important role in boosting transfection activity for these systems.

12

Also, the Ca2+

presumably promotes endosomal escape, increases cytosolic stability, and enhances
nuclear uptake of the DNA. 5 1 However, CaP-based gene carriers suffer from poor
reproducibility of transfection activity.

Stabilizing CaP carriers with lipids is

currently underway to solve this issue. 47 Recent studies have reported that carbon
nanotubes (CNTs) can deliver therapeutic agents, including DNA and RNA, to target

Drug payload
Biocompatible
coating

Encasulated
therapeutics

Targeting moiety
(antibody, peptide)

Radionucleotide; positron
emission tomography (PET)
tracer (18F)
Linkers
MRI contrast agent
when core consists
of iron oxide

Optical tag: visible or near
infrared (NIR) fluoresence
imaging
(fluorescence dye,
quantum dots)

Figure 1.4. Example of multifunctional nanoparticles for theranostic applications.
disease sites. Most recently AI-Jamal el al. demonstrated delivery of siRNA in vivo
to central nervous system by using ammonium salt functionalized CNTs. 52
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Magnetic nanoparticles for gene transfer

Mah' s group first demonstrated external magnet-assisted enhancement of viral
transduction using magnetic nanoparticles.53 Nucleic acid delivery assisted by an
external magnetic field is now commonly known as magnetofection (Figure 1.5).54
Although oxide nanoparticles, like CoFe20 4, NiFe204, and MnFe20 4 exhibit superior
magnetic properties, their use in biomedical applications is challenged by the toxicity
of these systems.55 In contrast, iron oxide nanoparticles, such as Fe304 (magnetite) or

Np·DNA
complex
or magnetoplex

Transfected cells

/

Cells

Magnetic
plate

~--

t

Enhanced transfection
due to sedimentation
effcets

• cationic iron oxide nanoparticles

Figure 1.5. Magnetofection: External magnetic field assisted transfection.

y-Fe20 3 (maghernite), are relatively safe and have been used in humans use as MRI
contrast agents (Feridex I.V.).

Many research groups, such as Lee et al. 54 have

modified the surface to increase the transfection efficacy and reduce the cytotoxicity.
To achieve enhanced transfection activity with minimized toxicity, investigators used
various surface adjuvants, such as anionic surfactants (oleic acid),s6 polymers (PEG,
poly-L-Iysine, dendrimers),57, 58, 59 carbohydrates (chitosan),6o silica particles
(MCM48),61 proteins (serum alburnin),53, 62 phospholipids,63 cationic cell penetrating
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peptide (TAT peptide),64 transfection reagents (lipofectamine

2000),65

and even

viruses. 50, 51,66 These surface modifiers prevent agglomeration and add functionality
that may be further used to conjugate other polymers, such as PEL Most of the
researchers employ PEl or a modified PEl coating technology to impart a positive
charge density to the magnetic nanoparticles. 63 ,

67, 68

Huth et al. reported that the

mechanism of magnetofection usng a PEl -based magnetic vectors, followed
essentially the same endocytosis process as the related PEl-based polyplexes.
Release of the genetic material also occurred in similar manner via the "proton
sponge" effect. 69 The same group also reported that the accelerated nucleic acid
sedimentation when using the magnetic nanoparticles is the chief force behind the
success of magnetofection. 66 The most noted and recent magnetic nanoparticle
mediated gene delivery literature is summarized in Table 1.1 (adopted from
Reference 65).

Although magnetic assistance enhances DNA/siRNA transfection

activity many fold, the transfection activity of these magnetic vectors suffers severely
when the magnetic field is absent. This is likely to be problematic for gene transfer in
vivo. Li et al. 55 very recently reported successful delivery of pDNA to a lung tumor

model in mice without magnetic assistance using a PLL-coated magnetic vector. A
second major concern of these PEl coated magnetic carriers is their cytotoxocity,
which is associated with the toxic effects of PEL
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Modifying agent

Cells/tissue

2011

Magnetic
nanoparticles
Fe 304

PEI, streptayidin

2011

Fe30 4

2010
2010
2009

PolymagO
Fe30 4
Fe30 4

2009

Fe 3 0 4

Poly(propy leneimine)
dendrimers
Tat peptide
Silica
Oleic acid,
phospholipids
Poly-L-Iysine

NIH3T3,
HeLa
Saos-2
osteoblasts
U251
NCI-H292
HSC-45

Year

Lung tissue

Magnetic
assistance
Yes

Reference

Yes

56

Yes
Yes
Yes

61
58
60

No

55

63

Table 1.1. Most recent and noted magnetic nanoparticle mediated gene delivery

literature (adopted from reference 65).
nanoparticles (Oz Biosciences, France).

Q.

Commercial PEl-coated iron oxide

Chapter 2 of this thesis is focused on designing a PEl-free nano-magnetic
vector that can transfer pDNA into host cells without external magnetic force.
Ultimately, we aimed to achieve an AMF-stimulated, heat-induced transgene
expression using a magnetoplex (magnetic nanoparticleeDNA complex) containing
heat a shock protein (hsp) pDNA, which will be discussed in Chapter 2 of this thesis.
To accomplish our goal, we hypothesized using "click" oximation techniques to coat
the iron oxide nanoparticle surface with cationic moieties that facilitate pDNA
delivery.
As a part I of thesis, we aimed to achieve: (a) the design, synthesis and
characterization of cationic iron oxide nanoparticles for efficient gene delivery, and
(b) the evaluation of a heat-activated, hsp-promoted gene expression using thermal
energy generated by a magnetic vector under an external AMF-stimulus.
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1.3. Magnetic hyperthermia-induced drug delivery
Magnetic hyperthermia

According to the National Cancer Institute (Bethesda, MD), hyperthermia
(Greek for 'overheating') is a type of cancer treatment in which body tissue is
exposed to high temperatures (up to 45°C).

Research has shown that high

temperatures can damage and kill cancer cells, usually with minimal injury to normal
tissues. 7o By killing cancer cells or damaging proteins and structures within cancer
cells,7) hyperthermia may shrink tumors.

Thermoablation is another form of

thermotherapy where the temperature range is 46-56 °C. The higher temperature in
this case leads to direct tumor destruction by cell necrosis and carbonization.72 The
notion of hyperthermia is as old as anti-cancer medicine itself. Indeed, heat therapy
was first mentioned as a treatment of breast cancer more than 5000 years ago. 73 Since
hypoxic (poorly oxygenated) cancerous cells are much more resistant to radiation
therapy than that of euoxic (well oxygenated) cancerous cells, and since hypoxic
cancerous cells are more heat sensitive than euoxic cells,74 the combination of heat
and radiation therapy is a promising therapeutic modality.75
The main sources of thermal energy to induce hyperthermia fall into three
categories: (a) contact with externally heated liquids, (b) contactless applicator (e.g.,
irradiation using ultrasound, microwave, radiofrequencies, or infrared devices) and
(c) use of an inserted heating source (probes, laser fibers, and mediators).76 Unlike
other inserted heating sources, mediators convert the electromagnetic energy into heat
when exposed to an external electric or magnetic field. Macroscopic mediators are
inserted within the body via surgical procedure, whereas micro- or nano-scaled
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mediators are injected as particle dispersions. These mediators are heated either by a
captive applicator, or by applying an inductive applicator to magnetizable particles,
where the electric component (E-field), which can lead to uncontrollable heating of
the tissue, is lowered to the benefit of magnetic field (H-field) to generate heat
energy.77 Inductive mediators seem to be more useful because cells do not contain
any intrinsic magnetic materials that could generate uncontrolled heat in an
alternating magnetic field.

For patient comfort, the frequency of an alternating

magnetic field (AMF)-induced hyperthermia should be higher than 50 kHz to avoid
neuromuscular stimulation and less than 10 MHz for the appropriate penetration
depth of the frequency-field. 78 Surgically inserted ferromagnetic rods have been
placed into tumors to serve as interstitial macroscopic mediators. 79 The basic
limitations of this technique are stressful surgical interventions, lack of accessibility
to tumors, potential migration of the rods, and non-uniform temperature patterns.
The most recent magnetic hyperthermia models are based on micro- or nanosized mediators in the form of an injectable colloidal dispersion of magnetic particles.
Magnetic nanoparticle-mediated heating occurs via two main mechanisms: (a)
external AC magnetic field supplies energy and assists magnetic moment rotation by
overcoming the energy barrier (E

=

KV; K is the anisotropy constant, and V is

volume of the magnetic core) so that energy is dissipated when the particle moment
relaxes to an equilibrium orientation, a phenomenon known as Neel relaxation; and
(b) rotational Brownian motion can also generate heat from magnetic nanoparticles

within a carrier liquid due to the torque generated on the magnetic moment by an
AMF. 73

The prerequisite criterion for clinical application is nontoxicity of the
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magnetic nanoparticles.
nanoparticles with
investigation.

To date, magnetite (Fe304) and maghemite (y-Fe203)

satisfactory

biocompatibility

have

been under

intensive

Gilchrist reported the first application of iron oxide mediated

hyperthermia in vivo in 1957.

The first Phase I clinical trial of magnetic

hyperthermia was done by MagForce Nanotechnology Co. (Berlin, Germany) in 2005
with 14 patients suffering from glioblastoma. In this trial, the feasibility of magnetic

Figure 1.6. AMF applicator for humans: NanoActivator™, MagForce
Nanotechnologies AG, Berlin. A fiber-optic thermometry unit is part of the
applicator. Image was taken from Magforce website.
hyperthermia as a therapy was evaluated usmg a 100 kHz AMF applicator
(NanoActivator™, MagForce, Germany, Figure 1.6) and amino silane-coated iron
oxide nanoparticles (NanoTherm™, MagForce). 80 Hyperthermia was well tolerated
with radiation and with minor or little side effects. Signs of local tumor control were
observed.6 The Phase II trail of this study is in progress with 65 patients. 81 In fact,
this hyperthermia therapy was cleared for the market in European Union countries
last year, and has begun the treatment in patients in Germany under "an individual
19

patient agreement." Investigators in Japan also have reported the clinical application
of magnetic hyperthermia for melanoma treatment. 82
In summary, there is exciting evidence that raises the prospect of therapeutic
application of magnetic-hyperthermia in humans. The continuous effort in building
proper AMF generators for inducing magnetic hyperthermia in humans, gaining idea
of biodistribution of these nanoparticles, and acquiring knowledge of magnetic
nanoparticle toxicity is definitely strengthening the belief that AMF-induced
magnetic nanoparticle-mediated thermotherapy will be a viable treatment option.
Magnetic hyperthermia-triggered drug release

Magnetic hyperthermia opened a new avenue in stimuli-triggered noninvasive drug delivery technology whereby drugs encapsulated within thermosensitive polymers, gels, or lipids containing magnetic nanoparticles (for generating
thermal energy to change the conformation of the carrier matrix) could be stimulated
by exposure to an AMF to cause the release. Once at the target site, a drug is released
from the carrier upon AMF-induction to create a local high concentration of drug
resulting reduced side effects. To date, the AMF-triggered or magnetic hyperthermiainduced drug release platforms rely on two basic principles: magnetic heating (or
magnetic hyperthermia) of nanoparticle and a thermally responsive or (-rupturable)
coating.
Magnetic nanoparticles that are designed with the proper composition and size
to achieve heating using an AC magnetic field are generally placed inside a
thermally-responsive matrix.
nanoparticle,

or

a

A polymer can also be coated directly onto the

self-assembled

structure
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(e.g.,

micelles,

liposomes

or

polymersomes) can be devised to encapsulate the nanoparticles.

For biomedical

applications, the coating must open or partially rupture to release a drug when heated
above physiological temperatures. There are three mechanisms in which heat energy
can cause the structural change in matrix to release the drug (Figure 1.7). Generated
heat can swell the matrix and that can cause the release (Figure 1.7A). 83

In

squeezing-controlled release (Figure 1.7B), an already hydrated gel collapses rapidly
when heated, exuding water and much of the imbedded drug with the water. 84, 85 Liu
et af.

82

encapsulated doxorubicin (Dox, an anti-cancer drug) and iron oxide

nanoprticles inside of Pluronic F127 (FI27) matrix and demonstrated Dox release by
AMF induction.

Considerable volume shrinkage of F127 matrix due to heat

generated by magnetic hyperthermia causes the instantaneous release of Dox. This
system, however, is not suitable for in vivo applications because cargo release occurs
at 35°C, which is lower than the body temperature (37.5 °C). In another example,
Chaubey et al. used a naturally occurring genipin cross-linked gelatin nanoparticles
for encapsulating Fe304 nanoparticles and Dox. Drug release was observed when the
above system was induced by an AMF and this system is based on swelling
controlled release. 8o Iron oxide nanoparticles and drug encapsulated alginate
microsphere are also developed for magnetically controlled heat-responsive drug
release. 86, 87 In these cases, nanoparticle-induced thermal energy twists and shakes the
molecular chains, resulting in an increase of wall permeability that causes increased
diffusion of the drug (Figure 1. 7C). 84 BrUle et al. 86 observed cytotoxicity of this
carrier even before AMF-pulse, indicating premature drug release at 37.5 °C.
Because squeezing-based hydrogel systems would release a drug when heated, they
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are

preferred

over

swelling-controlled

systems

for

the

development

of

magnetothermally-triggered drug delivery systems. However, when a hydrogel is
placed in an aqueous environment (such as the human body), the gel will swell,
leaving the mesh open for drug diffusion and release prior to the triggering event, so a
squeezing-controlled release platform is not ideal for delayed triggering events. Hsu
et al. encapsulated lipophilic drug tetracaine and y-Fe203 nanoparticles (size 5-25 nm)
in a solid lipid nanoparticle (SLNP) matrix. Drug release was observed when the
vehicle was stimulated with a 25 kHz (frequency), 60 kAlm AMF. 88 Lipid transition
change was induced by heat generated from NP heating which caused diffusion of the
drug from the matrix. The low frequency of the AMF and high temperature rise (3750°C in 20 min) may face challenges in in vivo studies. Very recently Thomas et al
developed a smartly engineered magnetic core (Zn-doped iron oxide nano crystal)silica shell nano-system in which the anti cancer drug doxorubicin was entrapped via
diffusion.

The mesopores then were blocked by curcubit[6]uril (a macrocyclic

aminal) to prevent nonresponsive drug leakage at 37.5 °C. 89 The valves opened and
released the drug efficiently when an AMF-stimulus was applied.
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A. Thermo-responsive swelling

• •••
•
•
•
•

AMF
NP heating triggers
swelling of the matrix

Heat generated from magnetic
hyperthermia swell the matrix
to release the cargo

Magnetic nanoparticles (NP)
and drug encapsulated
in thermo-sensitive matrix
•

Magnetic nanoparticles (NP)

•

Encapsulated cargo

B. Thermo-responsive squeezing

..

AMF
NP heating triggers
contraction of the matrix

• •• • •
• ••
•
Heat generated from magnetic
hyperthermia squeeze the
matrix to release the cargo

C. Thermo-responsive opening of grafts

AMF
NP heating triggers
conformational change
of the matrix
Heat generated from magnetic
hyperthermia opens grafts to
release the cargo

Figure 1.7. Thermo-sensitive formulations for controlled release of payloads. A.
swelling, B. squeezing, and C. change in molecular conformation of matrix.
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To address the challenge of premature cargo release, we aimed to design
magnetic nano vehicle for AMF-controlled release that does not rely on a
thermosensitive material. As part II of my thesis, we set out to assemble a simple
drug-conjugated nano-sized magnetic drug delivery platform using "click" oximation
chemistry. Our final objective is to demonstrate AMF-induced drug release from our
custom magnetic vector.

Chapter 4 of my thesis will describe the development of

the first magnetic thermo-sensitive polymer-independent delivery system to address
the above stated challenges.
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CHAPTER 2

AMF-INDUCED hsp-PROMOTED GENE THERAPY
USING NANO-MAGNETIC VECTORS

2.1. Introduction
2.2. Results and Discussion
2.3. Conclusion and Future Directions
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2.1. Introduction

Logically, the control of therapeutic gene expression within tumors would
enhance the therapeutic impact of gene therapy. Along these lines, inducible plasmid
promoters to control gene expression would make the spatial and temporal targeting
of therapy more feasible. 90, 91 One smart strategy for induced gene expression is based
on chemical signaling. Examples include tetracycline-inducible or -suppressible gene
expression systems based on bacterial tetracycline operon.92 Disease-specific gene
activation systems have also been reported for induced gene therapy.93, 94 However,
two major obstacles of this strategy are: (a) tumor specific promoters must be
identified for each individual tumor, and (b) the ability to switch off the transgene
expression on demand is still problematic. 95
Among the various inducible gene expreSSIOn systems, external stimuliinduced systems have some unique advantages. Chief among them is the ability to
focus the inducing agent in a spatially targeted region. Such a system has been
described usmg gamma radiation and the Egr-l promoter. 96, 97 Targeting was
achieved either by radiotherapy or by systemic injection of radioisotopes
accumulating in the tumor cells.

However, radiotherapy has the disadvantage of

using ionizing radiation. In another approach, thermal energy can be used to trigger
gene expression in an inducible gene expression system. Among the most commonly
used heat-inducible promoters are the heat shock protein (hsp) genes, such as the
hsp70 family. Their transcription is upregulated in response to a toxic insult to the

cell, perticularly exposure to heat. 98 Importantly, the basal expression of genes
controlled by an hsp70 promoter region is nearly undetectable, whereas heat-induced
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expression is comparable to that observed with the popular cytomegalovirus early
(CMV) promoter. 99 Thus, it is feasible to restrict gene expression to a local region by
focusing the heat stimulus only on the target region (Figure 2.lA).

It has been

demonstrated that hyperthermia generated heat can be used for non-invasive and nontoxic alternative regulator for local gene expression using a thermo-inducible
promoter. tOO One of the main advantages of hyperthermia over radiotherapy is that
hyperthermia is potentially suitable for diseases other than cancer. There appear to be
long-term side effects in experimental cancer treatments using hyperthermia,
particularly in the temperature range that is most effective for heat-induced gene
induction. Among many examples, Huang et al. 95 have demonstrated that in vitro
expression of a heterologous gene with a heat shock protein 70 promoter could be
elevated 500 to lOOO-fold over background by heat generated from a hot water bath
(39-43 °C). Verkis et al. 101 demonstrated in vitro GFP (green fluorescent protein)
reported expression using thermo-inducible hsp promoter at 43°C.

Duration of

hyperthermia in this study was 30 min. Moonen et al. used the same heat shock
promoter and GFP reporter plasmid for heat-induced gene expression using MRIguided focused ultra sound technique to generate thermal shock in the tumor tissue. 102
In another study Smith et al. 103 activated an hsp-promoted luciferase reporter
construct for heat-induced gene expression using ultrasound-based hyperthermia.
The main obstacle with hot water bath hyperthermia is to generate enough
heat energy in tumors located deep within the body. This somewhat invasive therapy
may also face challenges in in vivo clinical applications.

UltrasoUfld-mediated

hyperthermia suffers with UfIdesirable temperature rise at the muscle-bone interface.

27

An alternative strategy to avoid whole body hot water bath hyperthermia or
ultrasound-induced hyperthermia for heat inducible gene therapy system is to apply
magnetic

nanoparticle-mediated

intracellular

AMF-stimulated

technology to induce localized gene expression (Figure 2.1B).

hyperthermia
Ito et al. have

combined TNF-a gene therapy driven by a heat-inducible hsp70 (heat shock protein
70) promoter with hyperthermia produced by AMP-irradiation of cationic liposomeiron oxide nanoparticle formulations. \04 Tang et al. also developed a heat-inducible
gene expression system in which thermal energy generated by PEl coated Mn-Zn
ferrite magnetic nanoparticles under an alternating magnetic field (AMF) was used to
activate gene expression. \05 They also used the h~p70 promoter. The NPs in this
system are challenged with biocompatibility issues due the composition of the Mn-Zn
and due to the PEl coating. In this experiment, however, authors injected a second
dose of nanoparticle formulation (2.6 mg or 4.6 mg of magnetic particles) before
AMF-induction, which might cause aggregation of particles in a particular zone of the
tumor and might result in non-uniform heating in tumor during clinical applications.
The successful fusion of PEl-free magnetic nanoparticle-mediated gene
transfer, AMF-induced intracellular nanoparticle heating and heat-induced apoptotic
gene expression would constitute a non-invasive, localized treatment of cancer. This
is our goal at the onset of my thesis research.
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A. Heat shock-promoted gene expression

Thermal energy, hyperthermia, 43 °C
heat activates hsp promoter

pDNA

-

Heat-stimulated gene expression
proteins generated by heat: luciferase,
GFP

heat shock
promoter gene
reporter gene ;
luciferase, GFP

B. AMF-induced heat-activated gene expression

AMF
AMF-induced NP heating activates hsp promoter

Heat-stimulated gene expression
luciferase, GFP produced

magnetoplex
+ +

PEl-coated cationic NPs

+
pNDA containing heat shock
promoter gene

Figure 2.1. Heat-stimulated hsp-promoted controlled gene expression. A. Thermal
energy controlled (e.g. , hyperthermia) heat-activated hsp-promoted gene expression.
B. Noninvasive AMF-induced NP heating triggerd heat-stimulated gene expression.
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2.2. Results and discussion
To achieve our goal, we ftrst set out to design a biocompatible PEl-free
cationic iron oxide (Fe 3 04) nanoparticle (NP) formulation to function as an efftcient
pDNA delivery vehicles.

In keeping with our research theme, we aimed to use

"click" oximation technology for NP surface manipulations. Chemoselective click
ligation of an aldehyde or ketone carbonyl group with an aminooxy counterpart to
form an oxime ether linkage (i.e., oximation, Scheme 2.1A) is a key step in the
synthesis of numerous bioconjugates. 106, 107, 108 Oxime ether linkages also are used as
a mechanism for pro-drug generation, 109 and are present in FDA-approved
pharmaceuticals, such as fluvoxamine. l1O Very recently (May, 2011), Cho et a/. ll1
published a report in which they conjugated an aminooxy terminated 30 kDa PEG
linker to human growth hormone using oximation technique. This modifted hormone
(ARX201) bearing oxime ether linkage was synthesized to achieve a molecular size
suitable for minimizing renal clearance yet maintaining acceptable viscosity for
enhanced therapeutic effect. In fact, ARX201 is now in Phase II clinical trials.
Our ftrst strategy was to pursue the surface modiftcation of commercially
available dextran-coated NPs (fluidMAG-DX, Chemicell, Berlin, Germany) using an
oximation approach.

We hypothesized that dextran-coated magnetic iron oxide

nanoparticles (50 nm) could be activated for conjugation to cationic aminooxy
reagents by cleaving the vicinal diol groups of the carbohydrate domain.

Thus,

periodate oxidation of fluidMAG-DX would generate multiple surface aldehyde sites
(Scheme 2.1B) for reaction with cationic aminooxy reagents. We planned to condense
cationic quaternary ammonium aminooxy salts with the aldehyde groups to generate a
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positive charge density on the NPs for ultimate DNA-binding and for subsequent
transfection applications.

A.
R~ONH2 + 0Y'R' oximation.
H/R

R~ONY'R'
H/R
oxime ether

B.

fluidMAG -DX
Chemicell , Germany

Fe304 Core
Dextran shell
50nm
cationic aminooxy
reagent

+.++
Cationic NP

Scheme 2.1. A. Chemoselective "click" oximation between aminooxy and the carbonyl
group of either a ketone or aldehyde. B. Strategy for synthesizing a cationic NP: generate
aldehyde groups by periodate oxidation, and then react the oxidized NP with a cationic
aminooxy reagent.
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To initiate our above stated plan we first synthesized and characterized a panel
of novel quaternary ammonium aminooxy salts (Figure 2.2, 2.1-2.4) for use in the
final oximation step.lI2 We adapted Grochowski's methodology to synthesize these
cationic aminooxy reagents. I 13

The cationic amiooxy reagents can serve as

nucleophilic reagents to access cationic materials more readily than their electrophilic
counterparts l14,

115

because the chemospecifIc oximation reaction between aminooxy

and aldehydelketones is expected to be facile. Our interest in gene transfer l16, 117 and
the fact that hydroxyethylated polar domains enhance the transfection efficiency led
us to prepare hydroxyethyl-functionalized analogs 2.3 and 2.4. Consequently, we
devised a general synthetic route of the novel nucleophilic cationization reagents 2.1-

2.4.112

\~

H2NO~N~ONH2
2.2

~OH
\~

H2NO~N~OH
2.4

Figure 2.2. Panel of quaternary ammonium aminooxy reagents.

Synthesis of quaternary aminooxy salts

Reaction of the commercially available ethanolamines 5 and 6 (Scheme 2.2A)
with N-hydroxyphthalimide (NHP) under Mitsunobu conditions (equimolar amounts
of NHP/PPh3IDIAD) furnished phthaloyloxy amines 7.1 and 8.2, respectively.
Amine quaternization was best accomplished by gently warming the amines in
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methyl iodide (ca. 0.2 M). The resultant, crude ammonium iodides were treated
directly with hydrazine in ethanol to cleave the phthaloyl groups. Aminooxy reagents
2.1 and 2.2 were purified and isolated as filtrate from hot acetonitrile in good overall
yield.
Monosilylation of di- (6) and triethanolamine (12) was accomplished by
reacting an excess of each ethanolamine with TBSCI as the limiting reagent. The
resultant, mono-protected ethanolamines 9.1 and 13.1 (Scheme 2.2B) were then
transformed to the corresponding N-(2-hydroxyethyl)-functionalized ammooxy
reagents (2.3 and 2.4) using the path established for synthesis of reagents 2.1 and 2.2.
Desilylation of the more polar phthaloyloxy amine 10.1 proceeded smoothly on workup by stirring with aq. HCI, this approach did not work for phthaloyloxy amine 14.1.
In fact, reaction with aqueous HF instead of TBAF ultimately furnished the desired
final target 2.4. My laboratory colleague, Mr. Xuan Huang, synthesized the reagent
2.4.
The IH NMR and l3C NMR clearly indicated that phthaloyl group was
cleaved during hydrazinolysis process and aminooxy or -ONH2 group was generated.
IH NMR spectra of phthaloyl protected quaternary ammonium salt and 2.1 are
included (Figure 2.3).
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A.

I
a
I
HO~N'R - PhthO~N'R
5: R
6: R

=CH 3
=CH 2CH 20H

7.1: R
8.2: R

b,

2.1
(78%)

C

or

-

2.2
(65%)

=CH 3 (75%)
=CH 2CH 20Phth (72%)

B.
OH

~

r

N-R

-

2.3

PhthO~

b

r

N-R

-

d,e

R'O

R'O

6: R =CH3
a ~ R' = H

10.1: R' = TBS
(not isolated)
11.2: R' = H (71%)

9.1: R =CH 3

(65%)

or
2.4
(70%)

R' =TBS
12: R

=CH2CH 20H

a ~ R' = H

13.1: R =CH 2CH20H
R' =TBS

=

14.1: R CH 2CH 20Phth
C ~ R' = TBS (82%)
15.2: R
R'

=CH2CH20Phth
=H (86%)

Scheme 2.2. Synthesis of cationic aminooxy reagents. Reagents and conditions: A.
Phth = phthalimidoyl; (a) N-hydroxyphthalimide, PPh3, DIAD, THF, 0 °C - rt, 12 h;
(b) CH3I, sealed tube, 45°C, 2 h; (c) H2NNH2-H20, EtOH, rt, 12 h. B. TBS = tBuMe2Si; (a) TBSCI (0.2 eq), Et3N (l eq), CH2Ch; (b) N-hydroxyphthalimide, PPh3,
DIAD, THF, 0 °C - rt, 12h; (c) 48% aq. HF, THF, 0 °C - rt, 12h; (d) CH3I, sealed
tube, 60°C, 2h; (e) H2NNH2-H20, EtOH, rt, 12h.
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Figure 2.3. IH NMR spectra ofphthaloyl protected salt and 2.1 in DMSO-d6 .
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Preparation of cationic fluidMAG
We performed NaI0 4 oxidation on the fluidMAG-DX NPs to form aldehyde
groups at NP surface (Scheme 2.3).118 Although elemental analysis data of the
oxidized fluidMAG-DX initially indicated the presence of aldehyde groups at the NP
surface, inconsistent elemental analysis values also indicated poor reproducibility of
this step.

This raised a concern about the consistency of the quality of the

commercial fluidMAG-DX. Oximation then was employed to conjugate the cationic
mono-aminooxy reagent 2.1 to add positive charge density at the NP surface to

Figure 2.4. SEM micrograph of commercial fluidMAG-DX.
furnish cationic fluidMAG (CFM, Scheme 2.3). According to elemental analysis
data, we could succeed to conjugate only

~ 1.0%

nitrogen after oximation to the

CFM, whereas theoretical %N in CFM was approximately 6%. The functionalized
particles prepared from this strategy never showed encouraging magnetofection or
transfection activity in studies using breast cancer cells (MCF-7). Lack of nitrogen
content at the NP surface indicated lack of cationic head group, which is the reason of
poor transfection activity of the fluidMAG-DX derived formulation.

In fact, we

noticed inconsistent chemical behaviors of the commercial fluidMAG-DX from batch
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to batch. Size determination using Scanning Electron Microscopy revealed that the
size of the commercial particles were larger than the vendor's claim (Figure 2.4).
SEM images of these particles also demonstrated a large size distribution. For these
reasons, we abounded the strategy of functionalization of commercial material.

fluidMAG-DX
Chemicell , Germany

Nal04 (excess)
H20

Fe304 Core
Dextran shell
50nm

~~~ONH2
/

excess reagent 2.1 , H:P,
Na-acetate buffer (pH 5.5)

2.1

..
+1
-N
Cationic fluid-MAG (CFM)

1

o~ +
-N1

Cationic surface of the CFM

Scheme 2.3. Synthesis of cationic NPs. Aldehyde moieties are formed at the surface
of the fluidMAG-DX NPs by periodate oxidation. Subsequent oximation usmg
cationic aminooxy reagnet 1 then inputs a net positive charge to the particles.
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Development of magnetic lipid particles (MLPs)

Unhappy with the quality of the commercial fluidMAG-DX prepartion, we
decided to develop our own custom nano-magnetic delivery vector for polynucleotide
delivery. To initiate our new plan, we first synthesized negatively charged Fe304
nanoparticles (NP) according to a co-precipitation method described by Mikhaylova
et al.1l9 Zeta potential measurements revealed the NPs had a surface charge of -32
mY. X-Ray Diffraction (XRD) and Energy-Dispersive X-Ray Spectroscopy (EDX)
measurements confirmed Fe304 magnetite and Transmission Electron Microscopy
(TEM) indicated particles with an average 5-10 nm diameter.
Without the aid of established transfection lipids and their co-lipid
formulations, the use of lipid coated nanoparticle vectors for gene transfer remains
largely unexplored.

Our research group's interest in oximation and program on

developing non-viral gene delivery systems 1l6, 120, 121, 122 led us to devise a flexible
method for stepwise construction of a transfection-active lipid coating directly on the
surface of iron oxide nanoparticles. Inspired by the nanoparticle 'click' conjugate
work of Miller I 23 and Mirkin,124 we sought to harness click chemistry to attach lipid
side chains onto aminooxy functionalized NPs using oximation methodology
To functionalize the NP surface with an aminooxy layer, the NPs were treated
with an excess (ca. 3.3 wt. equivalents) of cationic aminooxy reagent 2.2 (Scheme
2.4). The resultant aminooxy-coated nanoparticles (NP-l) were readily isolated by
magnet-assisted sedimentation and, using this method repeatedly, were washed 2X to
remove any unassociated aminooxy compound.

Dry weight measurements

consistently indicated a deposition of2.2 on the surface ofNp·l in the range of 1.27-
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4

1.30 !-tmol/mg, which is nearly 2X10 aminooxy groups/particle. We hypothesized
that the close association of 2.2 with the nanoparticles presumably is driven by a
combination of hydrogen bonding and electrostatic interactions.

125

The relative

extent of these associative interactions is unclear. The observed reduction in zeta
potential for NP·l to -16 mV reflected a partial neutralization of surface charge by
the ammonium ion of 2.2.

FITC2

NP

NP'l

•

NP'1'FITC2

HO

NIo1

S~N~CHO
H
Scheme 2.4. Synthesis ofNp·1 and conjugation ofFITC2 to the Np·1.

We evaluated the availability of arninooxy groups on Np·l by performing a
labeling experiment. We used an aldehyde fluorescent probe FITC2 for this study
(Scheme 2.4). After mixing the particles with FITC2, conjugated were magnetically
separated and washed 2X with methanol to furnish Np·l·FITC2. FITC2 was mixed
with only NP in a same way to prepare Np· FITC2 that served as a control. The UV
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measurements indicated the aldehyde substrate FITC2 is bound to the nanoparticle
only when compound 2.2 is present (Figure 2.5).

FITC2 was not bound unless

compound 2.2 was loaded onto the NP fIrst, implicating the oxime ether linkage as
the tethering functionality.

4

FITC2

3

Abs.

2

Np·1

O+---~~~~=----,-------,--------.-----~

300
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800

Wavelength (nm)
Figure 2.5. UV-visible spectrum of NP-Ioaded with FITC2, Np·l and NPs. UVVisible spectroscopy measurements were taken of NP, NP·1, NP·1·FITC2 and
FITC2 at concentrations of 0.025 mg NP/mL (water). As a control, unmodifIed NPs
were reacted with FITC2.
We were gratified to fInd that reaction ofNp·1 with excess myristaldehyde (7,
Scheme 2.5A) resulted in smooth attachment of hydrophobic chains via oximation to
give the corresponding magnetic lipid particles (MLP, Scheme 2.5A). The MLP
formulation demonstrated a signifIcantly more positive zeta potential than NP·1.
Weight analyses indicate roughly one equivalent of myristaldehyde is attached during
the oximation step, suggesting that single chain lipid 8.1, or likely a mixture of lipids
8.1 and 8 (Figure 2.6A), is bound at the MLP surface and possibly as a surrounding
bilayer (Figure 2.6B), is most likely reason for the shift in zeta potential (+ 40 mV).
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A. Stepwise method

MeOH

MeOH

Spotential (mV)

NP

Np·1

MLP

-32

-16

+ 40

B. Direct method
-

\I~O"""N :;'
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/ ~O""N

~
8
MeOH. room temperature

Spotential (mV)

NP

dMLP

-32

+40

Scheme 2.5. Strategies for synthesis of lipid coated nano-magnetic carriers.
Conditions: Each functionalization step was done in methanol at room temperature
for 12 h; isolation and purification were performed via magnetic separation. Surface
charge (s-potential) measured in H2 0. A. Preparation of magnetic lipid particles
(MLP) using a stepwise oximation approach. B. Preparation of dMLP via direct
loading of oxime ether lipid.
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Evaluation of the transfection efficiency ofMLP in MCF-7 breast cancer cells
was done using a luciferase reporter gene assay (Figure 2.7). MLP-magnetoplexes

A
\

-

I~O"NY

+N

/ '------..ON H2

8.1

-

\

I~O"NY

+N

/ '------..OJ' N ~

8

B
NP surface - - - - - - - - ,

Figure 2.6. A. Cationic oxime ether formed on reaction with meristaldehyde at the
NP surface. B. Schematic representation of bilayer formation at NP surface.

(MLP·DNA complex) were prepared at various weight ratios by direct mixing with
the luciferase pDNA followed by application to cells in the presence of a static
magnetic field. The data (Figure 2.7) indicated that MLP transfection efficiency is
roughly equivalent or slightly higher than that of the commercial transfection agent
Lipofectamine 2000 (positive control) at magnetoplex weight ratios exceeding 120,
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while activity drops off rapidly at higher ratios. Not unexpectedly, given the negative
zeta potential of NP·l, magnetoplexes derived from Np·l did not transfect (400-600
RLUs).
Unfortunately, as with most magnetic nanopartic1e delivery systems, removal
of the magnetic field resulted in substantial loss of transfection activity for the MLPmagnetoplexes.
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Figure 2.7. Magnetofection of MCF-7 cells using MLP-derived magnetoplexes in
presence of 10% FBS. Results are expressed as total relative light units (RLU).
Transfections were performed in 24-well tissue culture plates using 0.025 mg luciferase
reporter construct (pCMVLuc) per well with 18 h transfection time. Each data point
reflects the mean value of three separate transfections and the standard deviation from
the mean. LFT = Lipofectamine 2000.
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Since additional myristaldehyde could not be attached by further reaction with
MLP, we probed whether direct attachment of the dual-chain lipid Sll2 to iron oxide
nanoparticles could be accomplished. Reaction of excess S with the NPs followed by
our washing protocol delivered dMLP, magnetic lipid particles formed on direct
exposure to the cationic oxime ether lipid. Lipid loading was measured at 1.25-1.35
/-tmol/mg.

The TEM micrograph of dMLP (Figure 2.8) shows spherical shaped

nanocrystalline particles around 5-10 nm in diameter.
Evaluation of dMLP in the transfection of MCF-7 cells (Fig. 2.9) revealed
notable

differences

in comparison

to

transfections

using MLP.

Under

magnetofection conditions (Figure 2.9A) and in the presence of serum, dMLPmagnetoplexes are considerably more active than MLP-magnetoplexes at all

Figure 2.S. TEM micrograph of dMLP.
magnetoplex ratios and substantially more efficacious.

The optimal dMLP-

magnetoplex-120 exhibits more than three orders of magnitude higher transfection
activity (ca. 1425-fold) than the transfection standard Lipofectamine 2000. More
remarkable are the activities of dMLP-magnetoplexes in the absence of a magnet
(Figure 2.9B).

The dMLP-derived magnetoplexes are not dependent on magnet-

assisted sedimentation for their activity, unlike MLP-magnetoplexes.

At

magnetoplex ratios between 90 and 540, the data indicate dMLP significantly
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promotes transfection relative to the positive control (e.g., magnetoplex-180 exhibits
>40-fold higher activity than Lipofectamine 2000).

We also examined if the

observed activity of dMLP is due to any unattached lipid 8 acting independently as a
transfection agent. We examined 8 at various lipid:DNA ratios without any helper
lipid and found it to be essentially inactive.
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Figure 2.9. Magnetofection (A) and transfection (B, no magnet) of MCF-7 cells
using dMLP-derived magnetoplexes in presence of 10% FBS. The results are
expressed as total relative light units (RLU). Transfections were performed in 24well tissue culture plates using 0.025 mg luciferase reporter construct (pCMVLuc) per
well with 18 h transfection time. Each data point reflects the mean value of three
separate transfections. Error bars show the standard deviation from the mean. LFT =
Lipofectamine 2000.
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Comparison of the measured zeta potentials for MLP- and dMLPmagnetoplexes (Figure 2.10) indicates different plasmid-binding properties.

The

dMLP formulations achieved net positive magnetoplexes at lower particle
concentrations.

Furthermore, the use of dMLP results in a fairly uniform

magnetoplex charge over a wide range of formulation ratios as reflected by the
consistent transfection activities observed for the dMLP-magnetoplexes, particularly
in the absence of a magnet, which is in agreement with transfection activities.
A cell viability assay was performed to evaluate the cytotoxocity of dMLPmagnetoplexes using alamarBlue kit (Invitrogen Corporation, CA). The cytotoxicity
study revealed that magnetoplexes derived from dMLP were less toxic towards MCF7 cells than Lipofectamine (Figure 2.11).
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Figure 2.10. Zeta potential measurements (H2 0) of MLp· (light bars) and dMLp·
magnetoplexes (dark bars) at various nanoparticle to pDNA ratios; the concentration
of NP in the aqueous particle samples was 0.1 mg/mL; magnetoplexes were
formulated at a concentration of 0.5 ~g pDNAIformulation; n = 3.
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Figure 2.11. Cell viability study of MCF-7 cells transfected with DNA alone (DNA),
Lipofectamine 2000 (LFT) and dMLP-magnetoplexes at various dMLP:pDNA ratios.
At 18 h post transfection, alamarBlue® was added to cells and the fluorescence
intensity (arbitrary fluorescent units) was measured at the onset (light bar) and then
measured again at 4 h post addition (dark bar, n = 3).
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AMF -induced hsp gene-promoted gene expression

With an efficient route to synthesize positively charged, lipid-coated magnetic
nanoparticles (dMLP) in hand, and having carefully optimized tansfection conditions

in vitro, we next sought to develop a heat-inducible gene expression system in which
the thermal energy generated by dMLP under an AMF -stimulus would be used to
activate the gene expression.

To pursue our goal we first purchased an hsp70-

luciferase reporter plasmid (hsp70-luc, SwitchGear Genomics, Menlo Park, CA,
product number S112961).

At first we wanted to examine the level of gene

expression when cells transfected using this hsp-construct were heated at 43°C in an
incubator (no AMF) and then compare the transfection levels to those of cells
incubated at constant 37.5 °C. Commercial transfection lipid Lipofectamine 2000
was used to transfect the hsp70 gene-promoted plasmid into the MCF-7 cells.
Transfected cells were heated at 43°C for 1 h according to the vendor's protocol and
a luciferase assay was then performed to evaluate the transfection efficiency 24 h post
heat-induction. Unfortunately we did not observe any encouraging promotion of gene
expression due to the heat-induction (only - 3X higher levels of expression for the
heat-treated cells, Figure 2.12).
The primary problem with this hsp-Iuc vector is related to the prolonged heat
shock of 1 h required to produce protein expression. This is likely to be a major
obstacle for NP-mediated AMF-induced gene expression. One hour AMP-induction
even in cell culture would cause cell death due to over heating from NPs, as
internalized NP surface will be at much higher than 43°C. Also long time AMFirradiation in animal study would face technical problems.
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Figure 2.12. Heat-inducible luciferase expression in MCF-7 cells. Transfection was
performed in 30 mm dish using 0.5 ~g pDNAIdish. Transfection activity was
expressed as RLU. Lipofectmaine 2000 was used to transfect at vendor's ratio. Cells
incubated at 37 °C was used as a control. LFT-37/43 °C is the lipoplex formulation
incubated at 37 ° or at 43 °C. Transfection activity was evaluated using a luciferase
assay kit according to the vendor's protocol after 24 h of transfection. Transfection
experiment was performed in duplicates.
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Thus, the hsp promoter gene is not potent enough to show very high level of
expression when transfected cells received a heat-induction. Verkis et al. 101 reported
80-90% GFP expression after 30 min of heat treatment when the cells were
transfected by their hsp-GFP construct. In their study hsp was taken from the plasmid
pD3SX, which was purchased from Stressgen Biotechnologies, Victoria, Canada. In
the work of Smith et al., 103 hsp-Iuc (luciferase reporter) construct showed 53 fold
enhancement of luciferase expression when cells were induced with heat (temperature
43°C) for 11 min than the transfected cells incubated at constant 37.5 °C. They also
used the same source of plasmid to construct the heat shock promoter from Stressgen
Biotechnologies. Unfortunately, when we pursued obtaining the same vector we
found that Stressgen Biotechnologies had merged with Enzo Life Sciences, Inc., NY
and the hsp-vector was discontinued. Our collaborator Dr. Geoffrey Clark (Brown
Cancer Center, University of Louisville, KY) also tried to contact various authors,
who had used the vector, but we did get not favorable responses.
However, further cloning technique could be required to re-engineer the
present plasmid to improve its expression efficacy at 43°C before use in AMFinduced hsp-promoted gene expression studies.
At this stage of the research, we turned our focus to a more achievable goal of
using AMF-induced hyperthermia to cause drug release from magnetic carriers. The
details of this research are discussed in Chapter 4.
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2.3. Conclusion and future directions

To our knowledge, the MLP and dMLP nano-magnetic gene delivery system
discussed in this chapter are the first demonstration of attaching lipid sidechains onto
iron oxide nanoparticles using click oximation methodology.

Elaboration of the

aminooxy-coated particles Np·l described herein into a magnetofection-active vector
avoids the use of PEl and requires only simple mixing with a hydrophobic aldehyde.
Using an even more direct approach, we demonstrated that reacting an ammonium
ion-based oxime ether lipid with iron oxide nanoparticles generated a highly active,
non-cytotoxic, magnetic transfection vector.

Notably, the resultant lipid-coated

nanovector dMLP functioned in the presence of serum to transfect a representative
cancer cell line without the assistance of a magnet.

According to our literature

search, our custom made dMLP NPs at present are the only polymer free magnetic
vectors that can transfect pDNA without magnetic assistance.

The poly-L-Iysine

(PLL) coated magnetic vector prepared by Li et al. (Chapter 1, Table 1.1) is the only
other reported transfection-active magnetic particle-based formulation thatt does not
require magnetofection condition.

Under magnetofection conditions, dMLP was

orders of magnitude more active in MCF -7 cells based on luciferase assay than the
industry-standard transfection agent. The results of our study demonstrate that Fe304
nanoparticles can function as transfection enhancers for an otherwise transfectioninactive material.
Given the emergmg field of in vivo applications, the development of a
magnetic vector that does not require a magnet for the transfection stage may enable
applications previously thwarted by less-effective magnetofection.
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Given a suitable plasmid construct that operates within 15-20 min of heat
activation, dMLP derived magentoplexes would lead to AMF-induced heat-actuated
localized gene expression.
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CHAPTER 3

CATIONIC OXIME ETHER LIPIDS:
A VERSATILE CLASS OF GENE CARRIERS

3.1 Introduction
3.2 Results and Discussion
3.3 Conclusion and Future Directions
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3.1. Introduction
Cationic lipids and their derived liposomes have become the most wellstudied and widely used synthetic, nonviral gene delivery systems since FeIgner et
al. 126 first demonstrated DOTMA mediated gene transfer in 1987. 127, 128 As discussed

in Chapter 1, the major limitations of viral vectors, such as associated immune
responses, limited polynucleotide carrying capacity and high cost,129,
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make

cationic lipids a promising alternative in modern gene therapy. The advantages like
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Figure 3.1. Common structural domain of cationic lipids.

low immunogenicity, the ability to transfect RNA or DNA of nearly unlimited
size, 131,

132

and ease of formulation techniques of cationic lipid-polynucleotide

complexes (lipoplex)J33 continue to attract interest aimed at developing safer and
more efficient cationic lipids for use as transfection agents. 134
Typical cationic lipid molecules, such as the dual chain lipids DOTMA and
DOTAP (Figure 3.1), contain a polar, positively charged (DNA binding) head group
connected to a hydrophobic domain via a linking functionality. These three principal
structural components of cationic glycerol-type lipids have been extensively studied
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efforts to improve lipid-mediated intracellular delivery of polynucleotides to

mammalian cells. 135
Over the years many structure-activity relationships have been determined 136,
l37

to understand the contribution of the hydrophobic domain to transfection

efficiency, including the variables of chain length, degree of unsaturation, and domain
asymmetry.138 Although the linker determines conformational flexibility, degree of
stability, and biodegradability of the cationic lipid, fewer direct structural
comparisons of changes in the cationic lipid backbone, or linking domain, have been
reported. The most well-known comparison being that of the diether DOTMA versus
the diester DOTAP. Among the most studied chemical functionalities comprising the
linking domain of transfection lipids are the ether, ester, ortho ester, 139, 140
carbamate,141 amide,142, 143 and phosphonol 44 moieties.
The use of oxime ether linkers in chemical biology and medicinal chemistry
have been discussed in Chapter 1 of this thesis. Oxime ether research has increased
dramatically in the past several years as the benefits of chemoselectivity and methods
for their exploitation have become better understood. Although oximation has been
used to attach ligands to transfection lipids, such as the ligation of carbohydrates,I45
and although an oxime ether-based assembly for siRNA delivery has been reported,146
no studies have examined the use of the robust yet biodegradable oxime ether linkage
as the backbone feature of cationic lipids for DNA delivery.
Our research group's long-term interest on developing lipid-based gene
delivery vectors 139, 147, 148 and interest in click chemistryl49, 150 inspired us to use
oximation as a facile approach to prepare non-toxic cationic oxime ethers and
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evaluate their transfection activity in several mammalian cells.

Based on the

promising transfection results using the oxime ether lipid coated NPs (MLPs)
discussed in Chapter 2, we prepared a panel of oxime ether lipids and evaluated their
gene expression activity using a conventional co-lipid formulation. A series of novel
oxime ether lipids were prepared (Scheme 3.1), containing different length of
hydrophobic chains to study the structure-transfection activity relationships in various
mammalian cells. The synthesis, characterization and transfection activity of these
novel oxime ether lipids is presented bellow.
3.2. Results and Discussion
Synthesis
We prepared a panel of cationic oxime ether lipids by reacting bis-(aminooxy)
ammonium salt 2.2 151 with the hydrophobic aldehydes dodecanal, tetradecanal, or
(Z)-octadec-9-enal (oleyl aldehyde) in methanol at room temperature to afford oxime
ethers 3.1, 3.3 and 3.5, respectively (Scheme 3.1).

In each case, the lipid was

obtained as a mixture containing two stereoisomers (diastereomeric ratio ranging
from approximately 2.3: 1 to 5.3: 1). The major diastereomer has (E)-stereochemistry
about each oxime C=N bond (as depicted in Scheme 3.1). The minor diastereomer
has an (E)-oxime ether as well as a (Z)-oxime ether linkage. The (E,E):(E,Z) ratio
was readily measured by integration of the well separated oximyl proton shifts in the
IH NMR spectra (Figure 3.2). For example, the oximyl proton shift for the (E)-oxime

ether side chain in 3.2 occurs at tJ = 7.45 ppm, while the (Z)-isomer shift appears at tJ
= 6.79 ppm. The isomer ratio was found to be susceptible to a variety of factors
including exposure to mild acid and heat. The stereochemical integrity of the oxime
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ether lipids is inconsequential in that isomerization can be expected in vivo.

Of

greater interest, however, is that the oximation approach used to prepare these
compounds delivers the lipids with intrinsic asymmetry in the hydrophobic domain.
Nantz et al. 147 and others 152 have recently noted the beneficial influence of
unsymmetrical hydrophobic domains in cationic lipid-mediated DNA transfection.
Consequently, we used the oxime ether lipids as obtained directly in transfection
experiments. To probe further the influence of an unsymmetrical hydrophobic

R-CHO
methanol, rt, 4h
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3.1: n,m 1 (C12), 61%
3.2: n, m 3 (C 14), 78%
3.3: n = 1, m = 3 (C 12,C 14), 27%

3.4,90%

Scheme 3.1. Synthesis of oxime ether lipid panel via oximtion route.
domain, we also prepared unsymmetrical analogue 3.4 (Scheme 3.1) by successively
condensing 2.2 with dodecanal and tetradecanal. The yield of3.4 of was poor (27%)
compare to others. The yield was not so great in the first step due to formation of
both bis- and mono-oxime ether lipids and then finally during attachment of the
second hydrophobic C w or CJ2-chain to the isolated mono oxime ether we observed
that column purified fraction was a mixture of 3.1, 3.2, and 3.3. Although, proton
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NMR looked good, HRMS measurement indicated that the final compound was
mixture of above three lipids. After careful purification we could only get 27% yield
of 3.3. Hydrophobic oxime ethers 3.1-3.4 were formulated as cationic liposomes
using equimolar quantities of colipid dioleoylphosphatidylethanolamine (DOPE) for
subsequent studies.
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Figure 3.2. IH NMR of3.2 in CD 30D. Oximyl proton shift of E, E isomer: 7.45 ppm
and Z, Z isomer: 6.79 ppm.
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Size and charge characterization
Particle size and zeta potential measurements on the oxime ether liposome
suspensions revealed that the particles were net positively charged with electrostatic
potentials in the range of 45-66 mV (Figure 3.3A). Liposomes derived from bis-C l8
lipid 3.4 were the largest, with particle diameters exceeding 200 nm, and the most
highly charged. Not unexpectedly, the liposomes derived from the shortest oxime
ether lipids 3.1 and 3.3 i.e., lipids prepared using dodecanal, had the smallest mean
diameters, near 150 nm. The trend in particle size versus particle charge correlates
well for this series of lipids.
The net charge of lipoplexes derived for the cationic lipids-DOPE, and pDNA
significantly influence the transfection activity of lipolex formulation. 153•
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Complexation of the oxime etherlDOPE liposomes with pDNA (pCMV-Luc) at
different ammonium nitrogen/DNA phosphate ratios (N:P ratio) gave the
corresponding lipoplexes. Zeta potential measurements of the oxime ether-derived
lipoplexes at N:P ratios of 3, 5 and 7 showed high positive values in the range of 3153 mV (Figure 3.3B). We observed that at these electrostatic potentials, minimal
lipoplex aggregation ensued. The oxime etherlDNA lipoplex suspensions were stable
at concentrations up to 0.33 mg oxime ether lipid per mL beyond one week. Particle
size measurements of the lipoplexes (Figure 3.3) indicated that the mean effective
diameter for all N:P formulations remained under 250 nm. Lipoplex size mirrored
closely the precursor liposome, with the lipoplex generally having an increase in
diameter by 20-50 nm (Figure 3.4).
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Transfection activity
After synthesis and thorough characterization of the lipids 3.1-3.4, and their
derived lipoplexes, we evaluated the transfecton activity of the lipid panel in human
breast cancer (MCF-7) and human lung cancer (H1792) cells using a CMV-Iuciferase
reporter plasmid in the presence of serum (Figure 3.5). Whereas the shortest chain
lipid 3.1 was essentially ineffective at all N:P formulations examined in MCF-7 cells
(2000±225 RLU), our studies revealed that transfection efficiency of lipid 3.2 in this
cell line at an N:P ratio of 7 was notably superior (greater than 2.5 orders of
magnitude higher activity than the commercial standards) to the commercial
transfection standard lipofectamine 2000 (3500±990 RLU) as well as to the popular
transfection formulation jetPrime (2500±209 RLU) (Figure 3.5A). The unsaturated
lipid 3.4 was also found to be efficacious in MCF-7 cells, although we observed
greater deviation in the measurement of transgene expression at the higher N:P ratios
using this lipid (Figure 3.5A). We did not observe an additional boost in transfection
activity on further amplifying the hydrophobic domain asymmetry by using
dissymmetric lipid 3.3, relative to the activities of lipids 3.2 and 3.4 in this cell line
(Figure 3.5A).
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Figure 3.5. Transfection of cells using lipoplexes formulated at different N:P charge
ratios: A. MCF -7 cells and B. H1792 cells. Results are expressed as total relative
light units (RLU). Transfections were performed in 24-well tissue culture plates using
luciferase reporter construct (pCMV -Luc; 0.025 I-tg / well) with 18 h transfection
time. Each data point represents the mean value of three separate transfections. Error
bars show the standard deviation (SD) from th mean. LFT=lipofectamine 2000,
jetP=jetPRlME.
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Only lipids 3.3 and 3.4 led to high transgene expression

ill

H1792 cells

(Figure 3.5B). In agreement with the observation reported by Nantz et al. 155 and
Fletcher et al. 156 on lung cell transfections, the presence of unsaturation in the
hydrophobic domain, such as is present in lipid 3.4, proved to be beneficial for
activity (Figure 3.5B).

Lipoplexes derived from lipid 3.4 effectively transfected

H1792 cells relative to the commercial controls (60-fold higher activity at N:P=7,
Figure 3.5B).

Interestingly, the enhanced asymmetry of lipid 3.3 resulted in

improved transfection of this cell line relative to the other saturated lipids examined
(Figure 3.5B).
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Figure 3.6. Transfection activity oflipid 3.2 in MCF-7 cells using 1 Jlg pDNAIwell
at N:P = 7. Transfection experiment performed in duplicate.
On a scale of 1 Jlg DNA per well, transfection of MCF-7 cells in a six-well
format using lipoplexes derived from lipid 3.2 at an N:P ratio of 7: 1 gave
approximately a 70-fold higher luciferase expression (as assessed by RLU per mg
protein) the lipofectamine 2000-derived lipoplexes (Figure 3.6). This result shows
that the most potent oxime ether lipid 3.2 is effective in high dose and wide range of
DNA doses in MCF-7 cells.
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A

B

c

Figure 3.7. MCF-7 cells were transfected with a GFP expression plasmid (0.1 !-tg per
well in a 24-well plate). Figure are presented as an overlay of green fluorescence
(visualized by fluorescent microscopy after 20 h of transfection) over the phase
contrast image: A. Cells treated with pDNA (negative control); B. Cells transfected
with lipoplexes derived from lipofectamine 2000 (positive control; vendorrecommended dose=0.25 mL); C. Cells transfected with lipoplexes derived from
lipid 3 at N :P=7.
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We also examined the gene-transfer capability of lipids with an oxime ether
linker domain using a green fluorescent protein (GFP) reporter vector to estimate the
transfection efficiency in MCF -7 cells (Figure 3.7).

Examination of cells by

fluorescence microscopy using an EVOS fluorescent microscope determined that the
results were in agreement with those of the luciferase assay.
Salivary gland cell transfection

To test the lipids in a non-cancer epithelial cell line, GFP was expressed in the
salivary gland cell line PAR ClO. This study was completed with the collaboration of
Professor Sven Gorr's research group at the University of Minnesota, School of
Dentistry.

Lipoplexes were formulated at an N:P ratio of 1.5, the optimal ratio

determined for lipids 3.1-3.4 in

thi~

cell line. GFP expression was evaluated 48 h

post-transfection. The fraction of transfected cells was quantified by flow cytometry.
Lipid 3.2 (C 14) transfected approximately 40% ofthe cells, lipid 3.1 transfected about
20%, while lipids 3.3 and 3.4 exhibited less than 10% cell transfection (Figure 3.8A).
Lipofectamine was slightly more effective in this cell line when used in excess (> 3X
recommended dose; Figure 3.8A) and comparable to lipid 3.2 when used at the
vendor-recommended dose (Figure 3.8B). These results suggest that lipids with an
oxime ether linker domain are suitable for the pDNA transfection of epithelial cell
lines and, depending on hydrophobic domain composition, competitive with the
transfection standard lipofectamine.
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Figure 3.8. GFP expression in PAR ClO cells. A. Cells were transfected (0.2 f-tg GFP
reporter construct) with lipoplex formulations derived from lipids 3.1·1.4 (N:P=1.5)
and excess lipofectamine 2000 (LFT; positive control; 1.6 f-tL); B. Comparison of
lipid 3.2 formulations at the indicated N:P ratio with LFT at the vendor· recommended
dose (0.5 f-tL). The transfection percentage of GFP expressing cells was analyzed by
flow cytometry 48 h post-transfection; n = 3.
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siRNA Transfection
RNA interference (RNAi) gained a tremendous attention since Fire, Mello and
colleagues first discovered the ability of double-stranded RNA to silence gene
expression in 1998.157 Tuschl and co-workers published their celebrated proof-ofprinciple experiment demonstrating that synthetic small interfering RNA (siRNA)
could achieve sequence-specific gene knockdown in a mammalian cell line in 2001 158
and the first successful use of siRNA for gene silencing in mice was demonstrated for
a hepatitis C target shortly after. 159 Theoretically, when using appropriately designed
siRNA, the RNAi machinery can be exploited to silence nearly any gene in the body,
giving it a broader therapeutic potential than typical small-molecule drugS. 160 Indeed,
it has already been reported that synthetic siRNAs are capable of knocking down
targets in various diseases in vivo, including hypercholesterolaemia/ 61 hepatitis B
virus (HBV),162 human papilloma virus,163 ovarian-cancer l64 and bone cancer. 165 In
order for these advances to be implemented in a clinical setting, safe and effective
delivery systems must be developed.
We tested the ability of our lipids to transfect epithelial cells with siRNA.
The previous study revealed that only lipid 3.2 transfected efficiently in P ARC 10
cells, so cellular "housekeeping" gene glyceraldehyde-3-phosphate dehydrogenase
was determined by measuring the reduction in GAPDH activity. GAPDH assay is a
rapid, convenient, fluorescence-based method for measuring the enzymatic activity of
glyceraldehyde-3 phosphate dehydrogenase (GAPDH) in cultured cells derived from
human, mouse, and rat. GAPDH is a tetrameric enzyme, composed of 36 kD protein
subunits. It catalyzes the oxidative phosphorylation of glyceraldehyde-3-phosphate
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(G-3-P) to bisphosphoglycerate (BPG). The GAPDH gene is generally recognized as
an ideal target for siRNA. GAPDH gene expression can be readily knocked down in
many different cell types by delivery of a validated control GAPDH siRNA (e.g.,
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Figure 3.9. Par CIO cells were transfected with siRNA for GAPDH and silencer
negative control. The enzyme activity was quantified 72 hr after transfection. Each
data point reflects the mean value of three independent experiments (n=9). Error bars
show the standard deviation from the mean.

Silencer® GAPDH Control siRNA). Thus, the efficiency of siRNA delivery can be
monitored by measuring the reduction in GAPDH mRNA or protein levels in cells
transfected with GAPDH siRNA relative to cells transfected with a negative control
siRNA.
Lipoplexes derived from 3.2 reduced GAPDH activity by 55±9%
(mean±SEM), while the control lipid, commerciallipofectamine RNAiMAX, reduced
GAPDH activity by 71±6% (n=9, Figure 3.9). This difference was not statistically
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significant (p=0.23).

These results suggested that lipid 3.2 effectively introduces

siRNA into epithelial cells.

Cytotoxicity Evaluation

We evaluated cytotoxicity of the lipids in MCF -7 and H 1792 cells using vital
dye trypan blue to stain the dead cells. The number of live cells remaining after
treatment was calculated as a percentage over the untreated control (Figure 3.l0A).
Our lipids were found to be less toxic than lipofectamine and jetPrime in both cell
lines (Figure 3.1OA), with cell viability comparable to untreated cells at all N:P
formulations examined.
For PAR C10 cells, the viability was determined by reduction of alamar blue
(Figure 3. JOB). None of the lipids reduced cell viability significantly compared with
untreated cells, confirming the low toxicity of lipids with an oxime ether linker
domain.
The PARC10 cell transfection experiments were done by Dr. Nandula in Prof.
GOIT'S

laboratory and it is worth mentioned that performance of these lipids were

reproducible, which is very promising for liposomal formulation. Also, in course of
our transfection evaluation studies we found that our cationic liposome formulations
are stable for six months at 4 cC.
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Figure 3.10. A. Relative cytotoxicity. MCF-7 (dk. bar) and H1792 cells (It. bar) were
transfected using either lipofectamine 2000 (LFT), jetPrime (JetP) or oxime ether
lipoplexes at the specified N:P ratio (value in parenthesis). Transfections were
performed in a 96-well format. Dead and live cells were counted 18 h post
transfection using a trypan blue stain (n=3); B. Cell viability assay. PAR CI0 cells
were transfected (N:P=1.5) with lipoplex formulations derived from lipids 2- 5 and
lipofectamine 2000 (LFT; 1.6 rnL). After 48 h, the cell viability was measured by
calculating the percentage reduction of alamar blue dye. n = 3
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3.3. Conclusion and Future Directions
We have demonstrated that the facile aminooxy-carbonyl click reaction can be
used to rapidly assemble transfection lipids furnished with asymmetric hydrophobic
domains. 117 The data show that lipids containing an oxime ether linking domain are
well tolerated by both cancerous and noncancerous epithelial cells. Furthermore, with
appropriate tuning of hydrophobic domain composition and N:P formulation,

ONH 2
( -----",,0 NH2
I- +N '"
/ ----"ONH 2

Tetradecanal (2.1 eq .)
methanol

3.5

3.6

T

Cell targeting lipid
T = cell specific targeting moiety

Figure 3.11. Synthesis of prototype oxime ether lipid for cell specific targeting.
lipoplexes derived from oxime ether lipids readily transfect representative epithelial
cell lines with excellent activity relative to established transfection agents.

Our

research using the cationic oxime ether lipid panel shows that this functionality is
suitable choice for linker domain. Given the biological compatibility of oxime ethers
and their ease of formation, this functional group should find much application in the
future design of transfection vectors. The ability to transfect epithelial cells could
have clinical applications, as epithelial surfaces are readily accessible and attractive
targets for gene therapy protocols that aim to express theraputic proteins in vivo. In
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fact, in vivo study of siRNA delivery in salivary gland using the lipid 3.2 is presently
undergoing at the Professor Sven Gorr's laboratory. The ability to simultaneously
transfect pDNA and siRNA with a single reagent now opens potential applications to
express therapeutic proteins in cells that are simultaneously modified by gene
knockdown.
In regards to future direction, we have designed a prototype dual chain oxime
ether lipid (3.6) that has a free aminooxy group for attaching targeting ligands or
elements for cell specific delivery (Figure 3.11).

The potential of this lipid for

targeted gene delivery will be evaluated in near future.
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CHAPTER 4

IRON OXIDE NANOPARTICLE-MEDIATED,
AMF-TRIGGERED DRUG DELIVERY

4.1. Introduction
4.2. Results and Discussion
4.3. Conclusion and Future Goals
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4.1. Introduction
For therapeutic applications, an external and noninvasive technique of
actuation can be beneficial to achieve a desired therapeutic effect. The best-known
examples of such a strategy include using gold nanocages, hollow gold nanospheres,
or other GNP-based platforms for drug delivery. These vehicles have been used as
heat-induced drug delivery systems.'66 They represents a class of nano-architectures
with a hollow interior andlor porous walls that undrgo a photothermal effect while
absorbing strongly at near-infrared region to generate heat while retaining their

laser on
•

Dox encapsulated
gold nanocage
covered with pNIPAAM

Dox release due to polymer
collapse resulting from laserinduced heat generation

gold nanocage
oIVVV

•

pNIPAAM
Dox

Figure 4.1. Schematic illustration of laser-controlled drug release.'
shape. 167 For example, Yavuz et al. 166 encapsulated the doxorubicin (Dox) into a
gold nanocage

covered with a thermo sensitive poly(N-isopropylacrylamide)

(pNIP AAM) derivative. On exposure to a laser beam with a wavelength that matched
the absorption peak of the Au nanocage, light was absorbed and converted into
thermal energy.

These researchers showed that the heat dissipated into the

surroundings, and the rise in temperature caused the polymer chains to collapse are
expose in the pores in the nanocage causing release of the pre-loaded Dox (Figure
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4.1).

They also demonstrated that when the laser was turned off, heating

immediately ceased and the temperature drop brought the polymer back to its
original, extended conformation, closing the pores and stopping the release.
In another example, Yang et al. 168 reported a delivery system consisting of a
poly(lactic-co-glycolic acid) (PLGA) matrix containing (Dox) and a gold over-layer
on a polymer matrix that also undergoes of a photothermal effect.

The temperature

of the carrier increased due to the surface plasmon resonance (SPR) effect of the gold

o

OH

0
OH

OMeO

OH

H

o",(oy
YOH
NH3

+

Dox·Hel

CI

-

Figure 4.2. Structure of doxorubicin.
layer when irradiated by near-infra red (NIR) light, and the resultant heat effected
cargo release from the softened PLGA matrix.
The concept of heat-triggered drug delivery using hyperthermia generated
from nano-magnetic carriers has already been discussed in Chapter 1. One important
advantage of magnetic hyperthermia-stimulated drug delivery using magnetic
nanoparticles over gold nanoparticle-mediated laser-induced delivery, such as
described above, is that magnetic particles can easily be viewed by MRI. Secondly,
laser-induction has the problem of shallow tissue penetration l69 • Where as alternating
magnetic field (AMF) can penetrate deep into tissue.
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More importantly, laser-

induced nanoparticle heating can generate uncontrolled heating (50-700C). 169
Magnetic hyperthermia is less risky and more controllable than laser-induced heating.
Given the fact that magnetic hyperthermia already has been examined in clinical
trials, 170, 171 AMF-induced drug delivery holds immense potential as an externally
controlled drug delivery platform.
The recently developed magnetic carriers for AMP-activated drug release are
described in Chapter 1. In most of the examples, the vehicle consists of a magnetic
nanoparticle encapsulated in a thermo-sensitive material.

The AMF-induced

hyperthermia (i.e., external stimulus) caused structural changes in these materials and
these in turn result in cause cargo release (Chapter 1, Figure 1.7) from the vehicles. 86 ,
172.

173, 174, 175 One problem of these systems is that many thermo-responsive material-

based magnetic carriers suffer from pre-mature drug release at body temperature (37
°C). Depending on the cargo, this may cause non-specific toxicity in vivo.
To address the challenge of premature cargo release, we aimed to assemble a
Fe304 nanoparticle (NP)-based delivery platform functions without the need for a
third component's structural or conformational change. In other words, our goal is to
design a thermosensitive, polymer matrix-free magnetic drug carrier that will respond
to an external AMF-stimulus to cause magnetic hyperthermia-triggered drug release.
Thus, the key innovation over existing carriers is vehicle simplification responsive materials will be incorporated.
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no thermo-

4.2. Results and Discussion
Development of magnetic carriers
We have chosen the potent, anti-cancer drug doxorubicin (Dox, Figure 4.2) as
our model drug.

Dox is an anthracycline antibiotic that consists of an aglycone,

hydroxylated quinine, and daunosamine sugar residue. Dox is a leading anti-cancer
drug because of its potent and broad spectrum of activity against diverse types of
cancer.

176

However, the efficacy of Dox treatments are severely impeded due to its

significant cardiotoxicity 177, 178 and nephrotoxocity.179

Oox.HCI

..

DMSO

NP
zeta pot.
(mV)

Np·AO

-27

sNp·AO·Oox

+3.2

Scheme 4.1. Stepwise loading of Do x on the NP.
To achieve our goal we strategized three routes to load Dox onto the Fe304
NP surface. As learned from our MLP/dMLP-mediated gene delivery program, we
first devised a stepwise loading of Dox onto the NP surface. In this route (Scheme
4.1), we first coated the NPs with the quaternary ammonium aminooxy reagent 2.3 to
synthesize Np· AO by simple mixing of the NPs with excess 2.3 (ca. 3.5 wt.
equivalents). Absorption of charged ligands on nanoparticle surfaces are well known
in the literature. 180, 181, 182 Recently Berret et al. 183 demonstrated that negatively
charged y-Fe20 3 nanparticles can be coated and consequently stabilized using block
copolymers containing a cationic quaternary ammonium group. The mechanism is
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based on electrostatic attraction between the oppositely charged entities. Alcoholic
hydroxyl groups are also well known for stabilizing iron oxide nanoparticles, e.g.,
dextran coated nanoparticles are well characterized and even commercially available.
We hypothesize that the positive charge of the cationic aminooxy reagent as
well as its hydroxyl groups are responsible for the efficient surface coating, specially
since the NPs are negatively charged

(~-potential

= -30 mY).

~-potential

measurement of Np· AO revealed that particles were partially neutralized at -19 mV.
We demonstrated previously (Chapter 2) that cationic aminooxy reagents can be used
as surface modifiers of NPs and that the aminooxy groups are available for ligation
applications. The presence of 2.3 at the NP surface provides aminooxy moieties for

°
OMeO

°

OH

OH

°

OH

o"roy

OMeO
0 .1% TFA, MeOH, 4 d, 90%

OH

OH

o"roy

YOH

YOH

NH3

+

NH2

CI

Dox·HCI

Dox·AO

Scheme 4.2. Synthesis of Dox·AO.
subsequent conjugation of Dox
(Scheme 4.1).

Via

an oximation reaction to yield sNp·AO·Dox

Dox has multiple carbonyl groups for reaction with aminooxy

functionality.
The fact that cationic oxime ether lipids tend to bind well to our NPs (Chapter
2), inspired us to devise our second formulation route. We first synthesized a novel
cationic oxime ether conjugate of Dox at the C-13 ketone position (Dox· AO, Scheme
81

4.2). To synthesize Dox·AO we modified the method described for synthesizing a
Dox-maleirnide conjugate at C-13 position as described by Kruger et al. l84 In brief,
2.3 and Dox were reacted in 0.1% trifluoro acetic acid in anhydrous methanol for 96
h at room temperature under nitrogen. The solvent was evaporated and Dox· AO was
purified via recrystallization from hot acetonitrile. Dox· AO was characterized by IH
NMR, I3C NMR and HRMS. I3C NMR spectroscopy revealed that oximation had
occurred at C-13 as expected. The I3C NMR chemical shift of C-13 changed from

A.
Dox'AO
DM SO

NP

dNP' Dox' AO

B.
Dox.HCI

•

DMSO

NP

Np·Dox

Scheme 4.3. Preparation of Dox loaded magnetic nanoparticie formulations. A. Direct
loading of Dox· AO. B. Only Dox. loading.
213.2 ppm in Dox· HCl to 162.6 ppm in the conjugate. In contrast, the I3C NMR
chemical shifts of the quinone carbonyl carbons (C-12 and C-5) were essentially
unchanged (Figure 4.3). The two extra signals between 50 and 55 ppm and three
extra signals between 60 and 70 ppm (Figure 4.3) correspond to the added carbons of
2.3. Also, chemical shift of alpha carbon to the amine group of the Dox· HCl and
Dox· AO remain essentially unchanged. HRMS analysis revealed the existence of
Mlz

=

1 species.

After synthesizing Dox· AO, we loaded this cationic analog onto
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the NPs directly (Scheme 4.3A) to furnish dNp·AO·Dox.

Reaction of NP and

Dox·AO in DMSO at room temperature for 12 h, followed by two magnetic
separations provided dNp·AO·Dox. After the first magnetic separation, the isolated
NPs were washed with methanol, and after the second wash we did not observe any
red colored supernatant indicative of free Dox-conjugate.
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CD 30D.
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The fact that Dox-HCl (Figure 4.1) is a hydrochloride salt and has a sugar
moiety encouraged us to examine a third strategy, the preparation of NP-Dox
(Scheme 4.3B).
We loaded Dox-HCl directly onto NPs assuming that the innate charge
attraction, and hydrogen bonding would be sufficient to keep Dox associated with the
NPs.
DOX=NO

.. ----

.

V
,

,,

,'+/\ "

; NOH,
, / \
:
,,
I

-.

,

"'---'"

We assume this is the region 'binding'
to the NP, so the footprint of this should
be calculated

/\

~N

OH

\
4.1

A good surrogate of
above binding domaain

Figure 4.4. Possible binding domain of Dox-AO.

In each of the NP functionalization steps we purified and isolated endfunctionalized particles by employing a magnetic separation technique that involved a
methanol washing followed by another magnetic separation.

The collected

supernatant that contained un-separated drug-loaded NP colloids were centrifuged at
10000 rpm (4°C for 15 min) to purify from unreacted Dox-AO and resultant NPpellet was mixed with magnetically separated NPs. The dry weight of purified (i.e.,
multiple washed) drug-loaded formulation provided the loading efficiencies. The
direct formulation (dNP-AO-Dox) showed maximum loading efficiency
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(~

0.37

~mol/mg

NP). A considerable amount of conjugate was also associated with the NPs

using the stepwise method (- 0.3

~mol/mg

NP, Table 4.1). The NP-Dox formulation

also indicated loading of Dox onto NP surface (- 0.l5

~mol/mg

NP, Table 4.1).

Loading calculation revealed that nearly 580 Dox-AO moleculeslNP.
calculation revealed -580 Dox-AO moleculeslNP.

Loading

A footprint calculation of

Dox-AO (number of molecules/ NP surface area), assuming the ammonium ion head

group binds to the NP surface, (Figure 4.4) revealed that approximately 1450
Dox-AO molecules can be attached to the NP surface. We hypothesize that the Dox

molecules likely are not lying flat on the particle surface, but actually are attached to
the surface via the polar linker groups (Figure 4.4). Thus, we calculated the footprint
using surface area ofa close surrogate 4.1 (Figure 4.4) of binding moiety of Dox-AO.
Since the aminooxy domain is smaller than the Dox molecule, more drug molecules
are predicted to be bound to the NP surface. This accounts in part for the smaller
quantity of Dox that was measured in the NP-Dox formulation relative to the
NP-AO-Dox formulations.
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Zeta potential measurements
We performed zeta

(~)

potential measurements to evaluate the surface charge

of the Dox-Ioaded nano-magnetic drug carriers (Table 4.1).

Surface potential of

sNp·AO·Dox was increased to slightly positive (+3 mY) from -27 mV (NP surface
potential) and it became moderately positive in dNP·AO·Dox to +17 mV (Table 4.1).
Dox·HCI attachment onto the NP surface also partially neutralized the NP surface

Formulation

Zeta potential
(mV)

Average
loading
"mollmg NP

AVel'age loading
(no. of drug
conju~ate

moleculeslNP)

NP
NP·Dox
sNP·AO·Dox
dNP·AO·Dox

-27~1.7

-20+-2.3
3~.1

17.1±3.1

-

-

0.15
0.3
0.37

Loading footprOOf:
no. of drug
moleculeslNP
sW'face area
-

235
470
580

587
1175
1450

Table 4.1. Zeta potential of NPs and drug loaded NPs (concentration: 0.3 mg NP/mL
PBS, n=3); and average loading of Dox as detennine.d by weight differentials.
potential to -20 m V. Charge neutralization of NPs indicated better attachment of
cationic oxime ether Dox analog to the negatively charged NP surface.

AMF -induced NP heating
Next we evaluated the AMF-stimulated heating of our NP-drug formulations.
Local temperature of surrounding media containing NP-formulation suspension
increased when dNp·AO·Dox (2.5 mg/ rnL NP by wt.) was subjected to an external
AMF (Easy Heat, Amritherm; frequency: 203 kHz, power: 350 A, 5 turn coil with 5
cm ID) for 18 min. The AMF parameters were chosen by noting previously reported
magnetic NP-derived hyperthermia-induced drug delivery demonstrations. Brule et

al. 86 applied 700 kHz frequency to release Dox from an alginate-based magnetic
microsphere. Zink and coworkers demonstrated cargo release from magnetic carriers
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using an AMP applicator at 500

kHz.185

Importantly, frequencies greater than 400

kHz are known to cause nonspecific heating in tissue. 186 Finally, Jordon et at. 187

Reported achievng intracellular hyperthermia in humans using a 100

kHz

AMF

frequency.
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Figure 4.5. AMP-induced hyperthermia of dNP-AO-Dox in PBS (2.5 mg NP by wt.)/
mL. Temperature of the surrounding solution was measured every 3 min using a fiber

optic temperature probe. n = 3.
With above demonstration, we decided to use an intermediate frequency of
200 kHz that can be generated readily using our 5-turn coil AMP applicator. The
power (350 A) was automatically set for this frequency. AMP-induction was started
after temperature of the medium reached at 37.0 °C and the temperature of the
surrounding solution was measured at every 3 min using an optical fiber temperature
probe (Neoptix Inc., Quebec, Canada). Our studies showed that the thermal energy
generated by the NP formulation on AMP -exposoure elevated the solution
temperature from 37 °C to

~43

°C within 12 mins.

continued AMP-exposoure (Figure 4.5).
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Little change occurred on

AMF -induced Dox release

Drug release studies using our NP formulations were performed following the
same AMF parameters as mentioned above. The Dox conjugate release study was
performed according to methods described in papers published by Brule 175 and Luo et
al. 188 Dox release was estimated every 3 min using a UV-spectrophotometer

measurements taken at 480 nm.

480 nm is the Dox absorbance of the quinone

system. Every 3 min 10 ilL of supernatant was aliquoted and diluted to 1 mL for
spectrometric reading.
We observed that an AMF-stimuli considerably increases Dox or Doxconjugate release from the magnetic carriers (Figure 4.6A) than what was released by
mere incubation at 37.5 °C. Both the dNP·AO·Dox and dNp·AO·Dox formulations
released

~65%

of their payload by 12 mins of AMF induction.

formulation released

~55%

The Np·Dox

of cargo at the same point of time (Figure 4.6A, green

line). Although s/dNp·AO·Dox released same average % of drug conjugate, they
released different amounts of drug since the loadings differed (Figure 4.6B).
According to our observations, no substantial drug release was detected at 37.5 °C
from the carrier (Figure 4.6C). It is evident from AMF-induced NP heating and drug
release studies that maximum average local temperature of 43°C can be achieved at
1i

h

mins, and this duration of AMF -exposoure can trigger ~65% of cargo release

from the nano-magnetic vehicles.

We also predicted that these NP formulations

would not exhibit cytotoxicity due to their lack of their at 37°C, and thus the
formulations might well function as 'prodrug'.
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Figure 4.6. Drug release profile. A. % of AMF-induced Dox and Dox· AO. Drug
release was calculated every 3 min using UV -spectrophotometer measurements taken
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Cytotoxicity studies

Encouraged by our AMF-promoted NP heating and drug release studies we
set out to investigate AMF-induced cytotoxicity of the NP formulations in a breast
cancer cell line (MCF-7). MCF-7 cells plated in a 30 mm dish at 4XI0 5 cells/ dish
were grown to 50-60% confluence. After treatments with varying amounts of the NP
formulations (0.25 mg, 0.5 mg and 0.75 mg NPs./ dish), the cells were incubated for 1
h at 37.5 °C before exposoure to the AMF. Dishes containing cells treated with
NP·drug formulations and untreated (control) were placed at the center of the

Figure 4.7. AMF generator: EasyHeat, Ameritherm, NY.

induction heater coil (Figure 4.7). Each dish was then subjected to an AMF for 15
min using the same parameters as described above. Cells treated with Dox (0.5 !-lmol)
and Dox·AO (0.5 !-lmol) served as positive controls.
As determined by the assay using the National Cancer Institute (Frederick,
MD) 60-cancer cell line screen, we found that Dox·AO was cytotoxic towards MCF-

7 cells (Figure 4.8 and Figure 4.9B). In regards to the other control experiments, cells
treated with NP formulations were incubated at 37.5 °C for 48 h to evaluate the
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cytotoxicity in the absence of AMF -exposure. We did not observe any abnormal
behavior of the untreated cells towards AMF induction (Figure 4.9B).

Also,

aminooxy coated NPs (NP·AO) were found to be nontoxic and surprisingly showed
no cytotoxicity even in the presence of AMF-exposure. Our studies indicated that
none of the NP-based Dox formulations (s/dNP·AO·Dox or NP·Dox) were cytotoxic
in the absence of AMF-exposure; however all the NP formulations displayed
significant cytototoxicty upon AMF treatment (Figure 4.9B). We found that the 0.5
mg dose (NP by wt.) was the most effective dose for AMF-induced cell death. Cells
treated with same amount of s/dNp·AO·Dox (NP by wt.) and exposed to an AMF
showed different levels of cytotoxicty. With AMF-exposure cell viability decreased
to -15% when the cells were treated with dNp·AO·Dox at the 0.5 mg NP dose
whereas cell viability decreased to -27% when cells were treated with sNp·AO·Dox
at the same dose. As discussed previously, dNp·AO·Dox has more conjugate (in
terms of mg) loaded on the NP surface than stepwise formulation, which in turn
released more conjugate on AMF-irradiation. Releasing more drug-conjugate from
dNP·AO·Dox than sNp·AO·Dox makes dNp·Np·Dox more cytotoxic in the

presence of AMF-induction.

We also hypothesized that the higher positive

~

potential of the dNp·AO·Dox promoted its cellular internalization. The Np·Dox
formulation was also active and demonstrated -50% cell inhibition when stimulated
by AMF (Figure 4.9B). The 0.75 mg NP dose showed aggregation in the cellular
media and was not evaluated further.
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Finally we monitored Dox and Dox·AO release in the MCF-7 cells pre-AMF
and post-AMF exposure using fluorescence microscopy (EVOS, Advanced
Microscopy Group, WA). Dox is easily observed using fluorescence microscopy due
its red fluorescent color and it appears as a bright red signal. Figure 4.1 OB shows the
fluorescence image of MCF -7 cells treated with Dox. Figure 4.1 OC suggests there is
no Dox release from NP·Dox before AMF-treatment. As clear from Figure 4.lOD,
AMF exposure triggers Dox release from the magnetic vector.
Very interestingly, when the above experiment was performed usmg
dNp·AO·Dox we did not observe any indication of DoxIDox·AO release in the cells

(Figure 4.10E) post-AMF treatment, but significant cell death occurred suggesting
release had occurred. This incident of fluorescent quenching was also observed when
cells were treated with only Dox·AO (Figure 4.lOF). We explain this phenomenon
by hypothesizing that Dox·AO binds its intracellular target DNA more effectively
than DOX,189, 190 which ultimately quenches the fluorescence of Dox. AO more
effectively. The fluorescence quenching is not due to the formation of the cationic
oxime ether linkage. The fluorescence intensity of both Dox and Dox·AO at the
same concentration is simmilar (Figure 4.11). Our results indicated that fluorescence
intensity was same for Dox and Dox·AO (Figure 4.11). Further more, when we
analyzed the supernatant from AMF-induced dNp·AO·Dox using HRMS, data
indicated the presence of only Dox· AO (M/z=2).
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A

B

c

D

E

F

Figure 4.10. Fluorescence images of MCF-7 cells. A. Cells treated with Dox. B.
Cells treated with Dox·AO. C. Cells treated with Np·Dox (No AMF). D. Post-AMF
treated with Np·Dox. E. Cells treated with dNp·AO·Dox (0.5 mg NP by wt. , No
AMF). F. Post-AMF treated with dNp·AO·Dox (0.5 mg NP by wt.). 0.5 !-lmolofDox
and Dox·AO was added to the cells. Fluorescence images were taken after 6h of
treatment using a fluorescence microscopy (ex/em = 480/590 nm)
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We performed a fluorescence measurement of the Np·Dox formulation. After
synthesizing NP·Dox, fluorescence activity was measured in ethanol using a
fluorescence plate. The fluorescence intensity of Np· Dox was 41 % less than the
fluorescent intensity measured for free Dox-HCI (Figure 4.12). We hypothesize that
the reduction is in part due to the spherical nature of particles, and one would expect
the edges of the sphere would receive less excitation than the face directly positional
toward the excitation signal.
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Figure 4.12. Fluorescence intensity of Dox and NP-Dox. 1 mmollL Dox
in ethanol.
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4.3. Conclusion and future directions

We developed a binary (NP + pharmaceutically active coating) external
stimuli-responsive magnetic drug delivery system in which a drug conjugate is loaded
onto NPs via simple electrostatic attraction and hydrogen bonding. Subsequent AMF
exposure breaks the electrostatic attraction forces as the NPs heat, thus constituting a
stimuli-responsive drug release. The temperature ofNP surface is high enough (> 43
°C) to promote ammonium drug conjugate release from NP surface. 191 This binary
nano-platform does not depend on a third variable, e.g., structural change of polymer
due to NP heating for cargo release.
We demonstrated that the cationic oxime ether analog of doxorubicin can be
attached to Fe304 NPs via simple mixing. The loaded NP formulations are nontoxic
to cells. However, on application of an AMF, the Dox payload released from the
particles. The magnetic nanoparticle delivery system was functionally demonstrated
using MCF -7 cells and shown to be effective when the external AMF stimulus was
applied. Our AMF-applicator parameters are well within the safe range for treatment
of mammals as described previously and in present 189 clinical trials of magnetic
hyperthermia.
The future of our magnetic delivery system largely depends on animal
studies. Effect of various oxime ether drug-conjugates (e.g.; one, two, or three
hydrooxy ethyl groups on cationic aminooxy reagents) on drug loading and release
will be performed in near future. The effect of AMF-applicator parameters on NP
heating also remained to be optimized in near future, as the focus of the research
shifts to animal studies.
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5.1. Introduction

This chapter describes my contributions to a collaborative bioengineering
project focused on the development of a microchip-based human breath analyzer for
detection of volatile organic compounds (VOCs).

The project is a collaboration

among three research groups, those of Professors Nantz and Higashi (Chemistry) and
Fu (Chemical Engineering). Although this project is not directly related to my thesis
focus of drug delivery, the research does exploit the cationic aminooxy compounds
described earlier.
The microreactor fabrication, functionalization, and breath analyses were
performed by Dr. Xian Fu and his graduate student Mingxiao Li (Chemical
Engineering, University of Louisville).
Analysis of exhaled breath has become an important research arena because
of its potential and applicability in noninvasive health diagnosis, metabolite
bioinformatics, and drug discovery.192,

193,194,195,196

The gaseous portion of breath is a

complex mixture of atmospheric gases, water vapor, and trace volatile organic
compounds (VOCs). In 1971, Pauling reported the first gas-chromatographic analysis
of breath, and the study revealed the presence of a large number of VOCs in human
breath. 197 A number of recent publications l98,

199,200,201

suggest that the analysis of

exhaled breath promises to be a non-invasive diagnosis for early detection of
particulate cancers since some VOCs in exhaled breath represent metabolic output of
cancer tissues and cells.
One of the most critical challenges for the analysis ofVOCs in exhaled breath
is ultra-trace concentrations of VOCs and interference of complex gas mixtures.
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Exhaled breath contains more than 200 VOCs. Recently, several reports indicate that
some ketones and aldehydes in exhaled breath could be used for the diagnosis of lung
cancer at an early stage. 195, 196
Carbonyl metabolites are produced in biochemical pathways as intermediates
and some can be unique to a given pathway or process. However, even common
carbonyl metabolites can be attributed to specific processes when stable isotope
labeled substrates are metabolized (e.g. by human subjects) and detected by mass
spectrometry or NMR. 202, 203 Volatile ketones and aldehydes are also generated from
damaging oxidative reactions, such as lipid peroxidation. 204, 205 Therefore,
development of a new method for analysis of ketone and aldehyde VOCs in exhaled
breath has a tremendous potential to fulfill the breath analysis promises.
Ketones and aldehydes can be detected by proton transfer reaction mass
spectrometry (PTR_MS),206, 207, 208 or selected ion flow tube mass spectrometry (SIFTMS) without any preconcentration process. 209, 210 Most recently, solid phase
microextraction

(SPME)

with

adsorbed

0-2,3,4,5,6-

(pentafluorobenzyl)hydroxylamine hydrochloride (PFBHA) has been used for
analysis of aldehydes in exhaled breath by gas chromatography-mass spectrometry
(GC_MS).195, 196 SPME is a popular preconcentration method introduced a decade ago
as a rapid extraction technique for analysis of volatile compounds from a variety of
matrices. 2II

However, the smaller surface area of the SPME polymer extraction

phase and physical adsorption of aldehyde PFBHA onto SPME for its capture makes
it is also extremely difficult to improve upon, or even determine the volume of air that
is actually sampled by the SPME fiber. The quality of the fibers depends on the
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manufacturer, and the performance varies from batch to batch. Derivatization of
ketones and aldehydes by reaction with 2,4-dinitrophenylhydrazine has also been
used for analysis of carbonyl compounds in exhaled breath,z12 which has the
advantage of converting volatile aldehydes and ketones into stable, easy-to-handle
non-volatile analytes. However, this class of reagents was not designed to aid in
detection by modern ultra-sensitive ion sources such as nanoelectrospray FT-ICRMS.

To address the above stated problems, we aspired to design a breath analyzer
based on a microreactor approach to capture gaseous ketones and aldehydes from
exhaled breath using a chemoselective oximation technique.
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5.2. Results and Discussion
Proof of concept
To engineer a breath analyzer silica microchip-based aminooxy loaded, we
first designed a simple bench top proof-of-concept experiment, wherein silica gel (1.5
g) was first loaded with cationic bis-aminooxy reagent 2.2 (35 mg, 0.12 mmole) in
1:5 MeOH:dichloromethane (steps a and b; Scheme 5.1). An ampoule of acetone-d6
(1 mL) was placed inside of the RB containing dried silica gel coated with
quaternary aminooxy salt 2.2 and then RB was sealed to protect the functionalized
silica gel from laboratory ambient acetone (or other vapors containing ketones or
aldehydes). After 18 h, the acetone-d6 ampoule was removed and silica was analyzed

c. expose to

acetone- d6

2.2

a. 1:5 MeOH :DCM

+
Silica gel

1.5 h

b. remove solvent

ampoule.

~
{).
.

acetone- d6 ampoule
aminooxy coated silica

e. wash substrates
d. incubate18 h

from support

then remove
ampoule

1 :20 MeOH:DCM

filtration

f. Analyze
Filtrate analyzed
by FT-ICR-MS

Figure 5.1. Schematic diagram of acetone-d6 capture.
for adducts by first eluting all materials from silica (stage e and f, Scheme 5.1) and
then analyzed by FT-ICR-MS. MS analysis revealed that the aminooxy-coated silica
gel indeed captured acetone-d6 vapor efficiently (Figure 5.2).
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260.0

Microreactor design
With this result in hand, Dr. Xian Fu' s research group prepared a microreactor
fabricated on 4 inch-silicon wafer using standard microelectro-mechanical systems
(MEMS) fabrication technology? 13 Figure 5.3 shows an optical micrograph of the
fabricated microreactor. The fabricated microreactor is the size of a penny (Figure
5.3B).
The micropillars have high-aspect-ratio with dimensions of 50 fA-m X 50 fA-m X
250 fA-m created by dry reactive ion etching silicon. The distances from center to
center of the micropillars are 100 fA-m. The flow channel size is 7 mm X 5 mm. The

A

B

Figure 5.3. A. Optical micrograph of a fabricated microreactor with thousands
internal micropillars. B. Fabricated micropillar on a silicon wafer.
total empty space in the microreactor is about 5 fA-L.

There are more than five

thousand square micropillars within the microreactor corresponding to a total
micropillar surface area of about 260 mm2 • For introduction of the capture coating
and eventual gaseous samples, the inlet and outlet of the micro reactor were connected
with 190 mm O.D. , 100 mm J.D. deactivated fused silica tubes using a silica-based
bonding agent.
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Surface coating
The surface of the micropillars was functionalized usmg quaternary
ammomum aminooxy salt 2.1 151 (abbreviated as ATM in this collaboration) for
chemospecific

ketone

or

aldehyde

capture

(Scheme

5.1).

The

surface

functionalization of the channels and micropillars by A TM ions was performed by
infusing a known amount of the A TM iodide salt in methanol solution into the
microreactor channel from one connection port followed by evaporation of the
solvent under vacuum.

The slightly negative surface charge of silicon oxide

micropillars enforces the close association of A TM with the solid support, which is a
benefit of including the quaternary ammonium group in the design.

Capture efficiency
To test the capture efficiency of the microreactor, measured amounts of
deuterated acetone, acetone or propanal in the microliter range or lower (diluted in

o
."~N~ONH2

/1

ATM

RAR' (H)
ketone
aldehyde

micro pillar

'.+

"""N~

/I

ON

W
1

R' (H)

R

oxime ether

Scheme 5.1. ATM oximation traps ketones and aldehydes in the microreactor.
methanol) were injected into a high purity (99.9999%) helium gas flow stream
passing through the microreactor. As illustrated in Scheme 5.1, the adsorbed A TM
on the micropillars react with gaseous ketones and aldehydes via oximation to capture
the analytes as oxime ether adducts.
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Figure 5.4 shows the schematic test setup for preconcentration of ketones and
aldehydes by the microreactor. In brief, various quantities of deuterated acetone,
from 0.271 nmole to 0.271 mmole in methanol, were added to the 20 mL vial to
evaporate into helium flowing through the vial and then the microreactor. The vial
had a Teflon lined rubber septum connected to both helium source and the
microreactor by the silica capillary tUbing. Acetone-d6 was used in these tests to

He
Mlcroreactor Flowmeter

Pressure
gauge

Vial
Figure 5.4. Schematic flow diagram of the preconcentration setup.

avoid bias from any environmental trace acetone contamination. The microreactor
operated at an inlet helium pressure from 15 to 25 psi. The flow rate of helium
through the microreactor was 2 to 5 mLimin. After addition of acetone-d6 to the vial,
helium flowed for at least 30 min to allow completion of the acetone-d6 transfer into
the microreactor. After preconcentration, the microreactor was disconnected from the
setup.

Then, the microreactor was eluted by flowing 10 flL methanol portions

through the microreactor into a septum-sealed glass vial; each aliquot was analyzed
separately to gauge elution efficiency via mass balance. The collected elution
solutions were directly analyzed by nanoelectrospray FT-ICR-MS for 5 min.
Figure 5.5A shows a typical FT-ICR-MS spectral region that has oximation
product of ATM with acetone-d6 (165.18688m1z ion) as well as unreacted ATM
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cations (119.11793 m/z ion). Greater than 98% of total reacted ATM and unreacted
ATM was collected from the microreactor with the first 10 mL methanol aliquot.
There was no trace detectable ATM and ATM-acetone-d6 after flushing a total 40 !-lL
methanol through the microreactor. Thus, the transfer efficiency exceeded 98% for a
rapid 5 min, 10 !-lL elution at the benchtop, requiring no specialized equipment other
than septum-capped vials and a syringe. The total analytical recovery of the acetoned6 dosage was >98%. Figure 5.5A also indicates that trace acetone contamination

from ambient air was very low.

110

ATM-acetone d6
llUSCIII

I
I

B

AnI-lcetoD&d6
105.1"

/ .,nt-CPItO
Y

173.16487

Ant-C:JB.O
........ 1511.1«12

Figure 5.5. A. Positive-ion nanoelectrospray FT-ICR-MS spectrum of
preconcentrated deuterated acetone from the microreactor. B. A typical FTICR-MS
spectrum of an exhaled breath preconcentrated by the A TM-coated microreactor.
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Ketone and aldehyde capture in exhaled human breath

Further testing was performed using exhaled breath as a prelude to future noninvasive health diagnosis methods. After approval by the Internal Review Board at
the University of Louisville and after having obtained written informed consent,
exhaled breath samples were collected from nine voluntary healthy non-smoking
subjects in the age range from 20 to 40. The subjects breathed lL breath air into one
liter Tedlar bags. A mixed alveolar breath and non-alveolar breath was collected. The
Tedlar bags were purchased from Supelco (Bellefonte, PA, USA). The bags were
tested free of ketone and aldehyde contamination. After collecting exhaled breath,
the sample bag was connected to the inlet of the microreactor through septa and the
silica tube. The outlet of the microreactor was connected to an oil free vacuum pump.
Each microreactor was loaded with 365 nmole ATM. After the breath air in the
sample bag was evacuated, the microreactor was disconnected from the flow line and
then eluted with methanol as described above.

A 8mL solution containing 2.32

nmole acetone-d6 completely reacted with ATM in methanol was added into each
eluted sample for analysis by FT-ICRMS. The ATM-acetone-d6 adduct served as the
internal reference to estimate captured amounts of ketones and aldehydes. Fig. 5.5B
shows a typical FT-ICR-MS spectrum of exhaled breath. C} to Cl2 ketones and
aldehydes were detected.
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5.3. Conclusion
The results of this work show that a microreactor-based aminooxy coating
efficiently oximates gaseous carbonyl species for practical analysis of ketone and
aldehyde VOCs. The designed microreactor features thousands of micropillars that
uniformly distribute gas flow to maximize the interactions with ketones and
aldehydes in the gas flow, resulting in capture efficiencies higher than 98%.
Moreover, the key inclusion of a quaternary ammonium group in the design of the
coating of the micropillar surface greatly enhances electrospray MS analyses. Simple
elution of the entire microreactor coating including all captured analytes eliminates
sample transfer problems that have plagued previous preconcentration approaches.
This complete elution is enabled by the use of direct infusion nanoelectrospray
FTICR-MS, which has the resolution to avoid interference of analytes by the capture
phase.
Since the FT-ICR-MS instrument is very expensive (present price $ 1M) and
not common in many diagnosis facilities, we also considered applying this approach

Figure 5.6. Structure of AMA (5.1).

to the more widely used GC-MS technique. To make the miroreactor-based breath
analyzer more available and cheap, we have functionalized microreactors using the
commercial neutral aminooxy reagent ortho-(2-morphilin-4-yl-ethyl)-hydroxylamine
(or AMA, 5.1, Figure 5.6) to detect the oximated adduct by less expensive GC-MS.
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Initial studies revealed that capture efficacy of 5.1 is compareble to ATM. This work

.

IS

.

ongomg.
Various cationic and neutral aminooxy-based reagents will be synthesized and

will be tested for ketone/aldehyde capture using microreactor.

The ATM-Ioaded

microchip is now being tested for analyzing vapor generated from the lung cancer
tissue and cell culture samples. The micrometer size of the chip can be advantageous
for testing various unique atmospheres of cells. Due to the high sensitivity and easy
engineering, this chemoseletive microreactor-based vapor analyzer has great potential
for explosive detection, drug testing for athletics, etc.
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Experimental procedures
Chemistry
All solvents and reagents used in this thesis were reagent grade and were used
as received unless otherwise indicated.

All nanoparticies and nanoparticie

formulations were synthesized using HPLC grade methanol (Sigma-Aldrich).

Dry

THF and CH2Clz were obtained from SPBT-101 Bench Top Solvent Purification
System (LC Technology Solutions, Inc., USA).

Anhydrous DMSO and methanol

were purchased from Sigma-Aldrich. Doxorubicin (Dox·HCI) was purchased from
Selleck Chemicals (TX, USA).
Column chromatography was conducted on silica gel (Si02, Mesh size: 230400 mesh, EMD Silica Gel 60).

Thin layer chromatography was performed on

precoated silica plates (EMD Silica Gel 60 F254).

UV active compounds were

visualized by UV light (254 nm). The TLC plates were stained using iodine, or panisaldehyde,

or

with

phosphomolybdic

acid.

High

performance

liquid

chromatography (HPLC) purification was performed using a Waters Delta 600 with a
dual wavelength (214 and 254 nm detector) UV detector (Waters 2487 Dual
Wavelength Absorbance Detector).
NMR spectra were recorded with a Varian MR eH 400 MHz, BC 125 MHz)
or with a Varian Inova eH 500 MHz,

I3 C

100 MHz) spectrometer. IH and I3C NMR

spectra of Dox·HCI and Dox·AO were recorded using a Varian VNMRS 700
spectrometer eH 700 MHz,

I3 C

176 MHz). Infrared spectra were recorded on a

Mattson Galaxy Series FTIR 5000 spectrometer.
measurements were

performed using

Fluorescent spectrometric

a Perkin Elmer
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LS55

Fluorescence

Spectrometer. High resolution mass spectrometry (HRMS) of the compounds were
performed at the University of Louisville, Center for Regulatory and Environmental
Analytical Metabolomics (CREAMM) facility using Thermo LTQ-FT instrument.
Liposome and nanoparticle formulations were prepared in ultra pure water
(Milipore).

Sonication was performed using bath sonicator purchased from

Laboratory Supplies Co., Inc., Ithica, NY. Zeta potential and particle size analyses
were conducted using ZetaP ALS dynamic light scattering detector (Brookhaven
Instruments Corporation; Model 90 Plus).
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6.2. Experimental procedure of Chapter 2
Synthesis

N-(2-( aminooxy)ethyl)-N,N,N-trimethylammonium iodide (2.1)
To a solution of triphenylphosphine (15.3

g,

58.3

mmol) and N-

hydroxyphthalimide (9.50 g, 58.3 mmol) in THF (200 mL) at 0 °C was added
dropwise N,N-dimethyl-ethanolamine (5) (4.33 g, 48.6 mmol). After stirring 30 min,
diisopropyl azodicarboxylate (DIAD) (11.5 mL, 58.3 mmol) was added slowly via
syringe. The reaction mixture was stirred an additional 30 min at 0 °C and then
allowed to warm to room temperature. After 12 h, the solvent was removed by rotary
evaporation.

EtOAc (150 mL) was added to dissolve the residue followed by

successive washings with saturated aq. NaHC03 (3 X 100 mL), water (50 mL), and
brine (3 X 100 mL).

The organic layer then was dried (Na2S04), filtered, and

concentrated to -50 mL by rotary evaporation. The organic layer was cooled using
an ice bath and cold 5% aq. HCI (30 mL) was added. On complete addition, the
mixture was warmed to room temperature and stirred 20 min. The aqueous layer was
separated, washed with Et20 several times, cooled to 0 °C, and then made alkaline by
slowly adding saturated aq. NaHC03. The alkaline aqueous layer was extracted using
chloroform (3 X 50 mL). The combined organic phase was dried (Na2S04), filtered,
and the solvent removed by rotary evaporation to afford aminooxy phthalimide 7.1
(8.53 g, 75%) as a light yellow solid which required no further purification for use in
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the next step; IH NMR (DMSO-d6 , 500 MHz)

f)

7.82 (d, J= 5.0 Hz, 4H), 4.21 (t, J=

5.0 Hz, 2H), 2.60 (t, J= 5.0 Hz, 2H), 2.17 (s, 6H); BC NMR (DMSO-d6)

f)

163.7,

135.3, 129.2, 123.8, 76.1,57.4,45.9.
The phthalimide 7.1 (0.50 g, 2.13 mmol) was placed in a sealed tube and
iodomethane (6.5 mL) was added.

The mixture was degassed using a stream of

nitrogen and then the tube was sealed and warmed to 50°C. After 2 h, the sealed
tube was cooled, opened, and the solvent was evaporated (caution: fume hood
required) to afford the crude ammonium iodide as a light yellow solid; IH NMR
(DMSO-d6 , 500 MHz)

f)

7.89 (s, 4H), 4.67 (br s, 2H), 3.8 (t, J = 5.0 Hz, 2H), 3.24 (s,

9H); J3C NMR (DMSO-d6)

f)

164.0, 135.9, 129.4, 124.3, 72.3, 64.2, 54.2.

The crude iodide salt was dissolved in a mixture of EtOH (5 mL) and H20
(0.05 mL).

Hydrazine monohydrate (1.13 mL, 14.9 mmol) was added and the

reaction mixture was stirred 4 h at room temperature. The solvents were removed by
rotary evaporation and acetonitrile (10 mL) was added to the residue. The resultant
white turbid solution was warmed to 40°C for 10 min and filtered through a cotton
plug. Filtrate was evaporated and dried under high vacuum to furnish 2.1 (0.41 g,
78%) as a light yellow amorphous solid: mp 97-99 °C; IR (DRIFT) 3236, 3008, 1480,
963 cm- I; IH NMR (DMSO-d6 , 500 MHz)
2H), 3.07 (s, 9H);

13 C

NMR (DMSO-d6 )

f)

f)

6.23 (s, 2H), 3.91 (br s, 2H), 3.52 (br s,

69.3, 64.1, 54.0. HPLC analysis (C 18 5~m

column, gradient elution using 100% H20 to 100% CH3CN over 10 min at a flow rate
of 1 mLimin) indicated excellent sample homogeneity (98% purity, tr = 1.88 min).
The elution profile was monitored by UV absorbance at 214 nm. HRMS calculated
for CSHISN20+ (M+): 119.1179, found: 119.1178.
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-~----~------

\ I. I

H2NO~N~ONH2
2.2

N,N-bis(2-aminooxyethyl)-N,N-dimethylammonium iodide (2.2)

Using the procedure described for synthesis of2.1, N-methyl-diethanolamine (6) (2.0
g, 16.8 mmol) was transformed into the corresponding bis-(phthaloyloxyethyl)amine
8.2 (4.94 g, 72%); IH NMR (DMSO-d6 , 500 MHz) {) 7.81 (s, 8H), 4.19 (t, J= 5.0 Hz,

4H), 2.79 (t, J = 5.0 Hz, 4H), 2.30 (s, 3H);

l3e

NMR (DMSO-d6 )

{)

164.0, 135.6,

129.5, 124.1, 76.4, 55.9, 43.0. A portion of this material (0.50 g, 1.22 mmol) then
was treated with iodomethane in the manner described above to afford the
corresponding ammonium iodide; IH NMR (DMSO-d6 , 500 MHz) {) 7.87 (s, 8H),
4.71-4.73 (m, 4H), 3.96-3.98 (m, 4H), 3.37 (s, 6H);

l3e NMR (DMSO-d6)

{)

164.0,

135.9, 129.4, 124.3, 72.1, 63.3, 52.7. The crude ammonium iodide was treated with
hydrazine as previously described to give the crude aminooxy product. Purification
of 2.2 was accomplished by following the same procedure as described for 2.1. 2.2
was isolated as a light yellow solid (0.23 g, 65% yield): mp 105-107 °e; IR (DRIFT)
3294, 1469,960,929 em-I; IH NMR (DMSO-d6 , 500 MHz) {) 6.24 (s, 4H), 3.92 (br s,
4H), 3.57 (br s, 4H), 3.08 (s, 6H);

l3e NMR (DMSO-d6)

122

{)

69.1, 63.0, 52.3; HRMS

N-(2-aminooxyethyl)-N-(2-hydroxyethyl)-N,N-dimethylammonium iodide (2.3)
In a sealed tube, mono-phthalimide 11.2 (0.60 g, 2.28 mmol) was dissolved in
iodomethane (10 mL). The reaction mixture was degassed using a stream of N2
before sealing the tube. The reaction was heated to 50 cc. After 3 h at 50 cC, the
reaction was cooled and the tube opened. The iodomethane was evaporated (Caution:
fume hood required) to afford the corresponding ammonium iodide which was used
in the next step without further purification; IH NMR (DMSO-d6 , 500 MHz) [) 7.88
(s, 4H), 5.29 (br s, IH), 4.67 (br s, 2H), 3.85 (t, J= 5.0 Hz, 4H), 3.56 (br s, 2H), 3.24
(s, 6H);

I3 C

NMR (DMSO-d6 )

[)

164.0, 135.9, 129.5, 124.3, 72.2, 67.0, 63.2, 55.9,

52.6.
To a solution of the crude ammonium iodide in EtOH (5 mL) at room
temperature was added hydrazine monohydrate (0.86 mL, 11.3 mmol). After stirring
12 h at room temperature, the solvents were removed by rotary evaporation. The
residue was purified using same technique as before to give 2.3 as a white solid (0040
g, 65%): mp 120-121 °C; IR (DRIFT) 3400, 3238, 1477, 963, 933 ern-I; IH NMR
(DMSO-d6 , 500 MHz) [) 6.24 (s, 2H), 5.24 (br s, IH), 3.92 (br s, 2H), 3.82 (br s, 2H)

3.58 (br s, 2H), 3.43 (br s, 2H), 3.09 (s, 6H); \3C NMR (DMSO-d6 )

[)

69.2, 66.7, 63.1,

55.9,52.4; HRMS: calculated for C6H\7N20/ (~): 149.1285, found: 149.1284.
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2-(N-methyl-(2-tert-butyldimethylsilyloxyethyl)amino)ethanol (9.1)

To a solution of diethanolamine (6) (9.0 mL, 78.4 mmol) and Et3N (2.19 mL,
15.7 mmol) in CH2Cb (300 mL) at 0 °C was added slowly a solution of tertbutyldimethylchlorosilane (2.35 g, 15.7 mmol) in CH2Cb (150 mL). On complete
addition, the reaction was allowed to warm to room temperature. After 12 h, the
reaction mixture was diluted with CH2Cb, transferred to a separatory funnel, and
washed successively with saturated NaHC03 (3

X

150 mL) and brine (3 X 150 mL).

The organic layer was dried (Na2S04), filtered and the solvent removed by rotary
evaporation. The residue was purified by column chromatography (Si02), eluting
with a 1: 14 mixture of methanol: CH2Cb (product

IY 0.43), to afford silyl ether 9.1

(2.72 g, 75%) as an oil; IH NMR (CDCh, 500 MHz)

l)

3.68 (t, J = 5.0 Hz, 2H), 3.55

(t, J = 5.0 Hz 2H), 2.58-2.59 (m, 4H), 2.31 (s, 3H), 0.85 (s, 9H), 0.02 (s, 6H);
NMR (CDCh)

l)

I3 C

61.2, 59.3, 58.7, 42.6, 26.0, 18.3, -4.90; HRMS: calcd for

C 11 H27 N0 2SiNa [M+Nat requires 256.1708, found 256.1709.
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PhthO~

+~i-r

N-

11.2

2-(N- methyl-(2-phthalimidooxyethyl)amino)ethanol (11.2)

Using the Mitsunobu procedure described above for the synthesis of 2.1, silyl
ether 9.1 (1.0 g, 4.1 mmol) was transformed into the corresponding monophthalimide product. After work-up, the crude mono-phthalimide was dissolved in
EtOAc (20 mL) and treated with cold 5% aq. HCI (20 mL). After stirring vigorously
for 20 min at room temperature, the layers were separated. The aqueous layer then
was washed with additional portions of E120 (3

x

30 mL), made slightly alkaline by

addition of saturated aq. NaHC03, and extracted with CHCh (3

x

50 mL).

The

combined chloroform extract was dried (Na2S04) and the solvent was removed by
rotary evaporation to give 11.2 (0.80 g, 71 %) as an oil; IH NMR (CDCh, 500 MHz) [)
7.78-7.79 (m, 2H), 7.70-7.72 (m, 2H), 4.28 (t, J = 5.0 Hz, 2H), 3.57 (t, J = 5.0 Hz
2H), 2.82-2.85 (m, 2H) 2.61-2.63 (m, 2H), 2.32 (s, 3H);
134.7, 129.0, 123.7, 76.4,59.3,58.8,55.7,42.2.
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I3 C

NMR (CDCh) [) 163.7,

8or3.2

Dimethyl-his(2-tetradecylideneaminooxy-ethyl)-ammon-ium iodide (8 or 3.2)

Ammonium iodide 2.2 (0.05 g, 0.17 mmol) and tetradecanal (0.80 g, 0.39
mmol) were dissolved in methanol (3 mL) and stirred at room temperature. After 3.5
h, the solvent was removed by rotary evaporation and the residue was purified by
column chromatography (Si02 ), eluting with a 1:33 mixture of methanol:CH2 Ch to
afford 8 (0.09 g, 82%) as a yellow solid (2.7:1 mixture of (E,E):(E,Z) oxime ether
diastereomers); TLC (19:1, CH2 Ch:MeOH) Rj= 0.45; mp 59-60 °C; IR (neat) 1703
(C=N), 1467, 968, 920 cm -I; IH NMR (CD 30D, 500 MHz) major diastereomer, [)
7.58 (t, J = 5.0, 2H), 4.53 (m, 4H), 3.83-3.85 (m, 4H), 3.4 (s, 6H), 2.30 (appt q, J =
5.0 Hz, 4H), 1.58-1.61 (m,4H), 1.37-1.4 (m, 40H), 0.98 (t, J= 5.0 Hz, 3H); BC NMR
(CD30D) [) 154.9, 67.8, 64.8, 53.2, 33.0, 30.6, 30.3, 27.5, 23.7, 20.1, 14.4; HRMS
calculated for C34 H70N30 2+(~): 552.5463, found: 552.5467.
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Preparation Fe304 nanoparticies (NPs)
Fe304 nanoparticles (NPs) with an average particle size of 10 nm were
prepared without any additional stabilizer according to the procedure described by
Mikhaylova et al. 119 Typically, 5mL of a 0.1 M FeCh and O.2M FeCi) solution were
added dropwise into 50 mL of 0.1 M NaOH solution under vigorous stirring for 30
min at room under a N2 atmosphere.
immediately.

The color of the suspension turned black

The precipitated particles were collected and removed from the

solution by applying a magnet (Super Magnetic Plate, Oz Biosciences, France). The
supernatant solution was removed from the reaction mixture by decantation. The
isolated NPs were dried using a lyophilizer (55 mg, 94.8% yield).

The NPs were

characterized by TEM, EDX and XRD as described in the following subsections.

Synthesis of Np·l
NPs (5 mg) were suspended in methanol (3 mL) and sonicated 5 min at room
temperature.

To the suspension was added N,N-bis-(2-aminooxyethyl)-N,N-

dimethylammonium iodide (2.2, 15 mg). The reaction mixture was first sonicated for
5 min and then stirred at room temperature.

After 12 h, the coated NPs were

separated magnetically and washed with methanol.

The washing procedure was

performed for total three times and then the coated NPs were dried under high
vacuum for overnight to obtain Np·l (6.9 mg, 2X104 moleculesINP).

Synthesis of NP-FITC conjugates
FITC2 was prepared according to the method described by Trevisiol1 et

al. 214 To an aqueous suspension of Np·l (5 mL, Np·l concentration at 0.8 mg/mL)
was added FITC2 (15 mg). The mixture was sonicated for 10 min. and then water (5
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mL) was added.

After stirring at room temperature for 12 h, the Np·1· FITC2

particles were magnetically separated and washed according to the procedure
described above using methanol.

The separated particles then were isolated after

freeze drying to give Np·l·FITC2 (7.S mg).

Synthesis of MLP and dMLP
To Np·l (6.9 mg) suspended in methanol (S mL) was added myristaldehyde
(20.0 mg, 0.94 mmol). The suspension was stirred at room temperature. After 12 h,
the lipid-coated nanoparticles were isolated by magnetic sedimentation, washed with
methanol (2X), and then dried under vacuum S h to yield the magnetic lipid particles
(MLP; 7.8 mg).
To NP (S.O mg) suspended in methanol (S mL) was added N,N-dimethylbis(2-tetradecylideneaminooxy-ethyl)ammonium iodide (8; 11.0 mg, 0.016 mmol)
and mixture was sonicated at room temperature for 2 mins.

The suspension was

stirred 12 h at room temperature. The resultant particles then were isolated by
magnet-assisted sedimentation, washed with methanol one extra time, and dried under
vacuum S h to give dMLP (9.25 mg).

N anoparticle Characterization
Labeling study
UV-Visible

spectroscopy

measurements

were

taken

Np·l·FITC2 and FITC2 at concentrations of 0.025 mg/mL.
unmodified NPs were mixed with FITC2.
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of NP,

NP·l,

As a control,

TEM, EDX, and XRD measurement of NPs and dMLPs

Methanol suspensions of NP or dMLP samples were deposited on transmission
electron microscopy (TEM) Cu grids coated with a carbon film.

TEM

microstructures and energy dispersive X-ray (EDX) spectra then were measured using
a JEOL JEM 3200FS at 300 kV equipped with an EDX detector. X-Ray diffraction
(XRD) patterns were obtained using a BRUKER D8 diffractometer with a CuKa
radiation source (1 Y4 0.15418 nm). The phase identification was performed using
JCPDS-ICDD 2000 software (The International Centre for Diffraction Data; ICDD).
TEM, XRD, and EDX measurements of NPs were performed at the Institute
for Advanced Materials and Renewable Energy, University of Louisville. TEM
images of dMLPs were taken at the Indiana University (TEM facility).
Zeta potential measurements

The zeta potentials of NP, NP·l, MLP, dMLP and derived magnetoplexes
were measured in water using a ZetaP ALS dynamic light scattering detector
(Brookhaven Instruments Corporation; Model 90 Plus). The concentration of iron
oxide in the aqueous particle samples was 0.1 mg/mL.

Magnetoplexes were

formulated at a concentration of 0.5 !-lg pDNA.
Transfection and cytotoxicity evaluation
Cell culture

Human breast cancer cells (MCF-7) were purchased from American Type
Culture Collection VA, USA. Cells were grown to 50-60% confluency in DMEM and
1% Pennstrep (Mediatech, Inc, VA) with 10% FBS (Valley Biomedical, Winchester,
VA).
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Luciferase expression

Luciferase transfections were performed in triplicate using 0.025

~g

of pDNA

(pCMV Luc) /well in MCF-7 cells. MCF-7 cells were seeded up to 1 XI05 cells/well
in a 24-well plate to 50-60% confluence.

Magnetoplexes (MLp·pDNA and

dMLp·pDNA) were prepared at nanoparticle:pDNA ratios of 30, 60, 90, 120, 180,
360 and 540 by adding the required volume of aqueous suspension of MLP or dMLP
to a pDNA solution (3 mL, 0.025

~g

DNA/mL). 200

~L

of serum free DMEM then

was added to each magnetoplex solution followed by incubation for 30 min at room
temperature. The magnetoplex solutions were diluted to 600
DMEM, and then 200

~L

~L

with serum free

of the final magnetoplex formulation were added directly to

each well. For magnetofection, the cell plate was placed on top of a magnetic plate
(Oz Biosciences) for 1 hat 37.5 °C. After 18 h incubation at 37.5 °C, the cells were
lysed and luciferase gene expression was quantified using a commercial kit
(Promega) and luminometer according to the vendor's protocol. Lipofectamine 2000
(Invitrogen) was used as a positive control. Transfections were also performed in
similar manner without the assistance of a magnet.
Cytotoxicity assessment of the dMLP formulations

Cell cytotoxicity and proliferation of cells treated with dMLP formulations
were examined by an alamarBlue assay. After transfection of MCF-7 cells using
dMLP derived magnetoplexes (0.025

~g

of DNA/well) and incubation for 18 h, cell

viability was measured according to the vendor's (Invitrogen) protocol. Fluorescence
intensities were measured using a spectrofluorometer (Molecular Devices:Gemini
EM) by excitation at 540 nm and emission at 600 nm.
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6.3. Experimental procedures of Chapter 3
Synthesis

3.1

N,N-Dimethyl-N-2-((dodecylideneamino)oxy)-(2-( (dodecylideneamino)
oxy)ethyl)ethanaminium iodide (3.1)
Compound 2.2 (26.5 mg, 0.091 mmol) and dodecanal (35.4 mg, 0.19 mmol) were
dissolved in MeOH (3 mL) and stirred at RT. After 3.5 h, the solvent was removed in
vacuo,

and

the

residue

was

purified

by

silica

column

chromatography

(MeOH:CH2 CI2, 3%) to afford oxime ether lipid 3.1 as a white solid (34.6 mg, 61 %;
(E, E):(E, Z), 5.3:1): RFO.52 (CH2ChlMeOH, 9:1); mp: 155°C (dec); IR (neat):
1735, 1468, 966, 920 cm"l; IH NMR (400 MHz, CD30D) () (major diastereomer)
0.86 (t, J=6.8 Hz, 6 H), 1.25-1.45 (m, 28H), 1.43-1.48 (m, 4 H), 2.17 (dd, J=6.8, 7.2
Hz, 4 H), 3.20 (s, 6 H), 3.73-3.75 (m, 4 H), 4.40-4.41 (m, 4 H), 7.46 ppm (t, J=6.0
Hz, 2H); \3C NMR (100 MHz, CD30D) () 14.6, 23.9, 27.1, 27.3, 27.7, 30.4, 30.6,
30.9, 33.2, 53.4, 64.9, 68.0, 68.3, 155.0, 155.5 ppm; HRMS: rn/z [Mt ca1cd for:
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3.3

N,N- Dimethyl-N-2-( (dodecylideneamino)oxy)-(2-( (tetradecylideneamino)

oxy)ethyl)ethanaminium iodide (3.3)
Compound 2.2 (22.6 mg, 0.078 mmol) and dodecanal (7.2 mg, 0.034 mmol)
were dissolved in MeOH (1 mL) and stirred at RT. After 14 h, the solvent was
removed in vacuo, and the residue was purified by Si02 column chromatography
(MeOH:CH2Ch, 5%) to afford the intermediate mono-oxime ether as a yellow oil
(14.0 mg, 39 %; (E, E):(E, Z), 1.7:1): R.F0.25 (CH2Ch/MeOH, 9:1).
The C 12 mono-oxime ether intermediate (13.1 mg, 0.029 mmol) and
tetradecanal (9.1 mg, 0.043 mmol) were dissolved in MeOH (1 mL) and stirred at RT.
After 14 h, the solvent was removed in vacuo, and the residue was purified by column
chromatography (Si02; MeOH:CH2Ch, 3%) to afford unsymmetrical lipid 3.3 as a
yellow oil (13 mg, 69%; E: Z, 2.3:1): R.F0.48; (CH2Ch/MeOH, 9:1); IH NMR (400
MHz, CD30D) (major diastereomer) [) 0.84 (t, J=6.8 Hz, 6H), 1.23-1.26 (m, 36H),
1.44 (dd, J=6.8, 7.2 Hz, 4H), 2.15 (dd, 1=6.4,7.2 Hz, 4H), 3.18 (s, 6H), 3.69-3.72 (m,
4 H), 4.38-4.40 (m, 4 H), 7.44 ppm (t, J=6.2 Hz, 2H);

\3 C

NMR (100 MHz, CD30D)

[) 14.6,23.9,27.1,27.3,27.6,30.4,30.6,30.7,.30.8, 30.9, 33.2, 53.3,64.9,68.0,68.4,
I
155.0, 155.5 ppm; IR (neat): 1728, 1467, 964, 942 cm- ; HRMS: m1z [Mt calcd for:
C32H66N30t: 524.5150, found: 524.5172.
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3.4

N,N- Dimethyl-N-2-( « (Z)-octadec-9-en-l-ylidene)amino)oxy)-(2-« «Z)-

octadec-9-en-l-ylidene)amino)oxy)ethyl)ethanaminium iodide (3.4)
Compound 2.2 (19.7 mg, 0.068 mmol) and cis-9-octadecenal (37.8 mg, 0.142
mmol) were dissolved in MeOH (3 mL) and stirred at RT. After 3.5 h, the solvent
was removed in vacuo, and the residue was purified by column chromatography
(Si0 2; MeOH:CH2Ch, 3%) to afford oxime ether lipid 3.4 as a yellow oil (45.8 mg,
90.0%; (E, E):(E, Z), 3.0:1): RrO.51 (CH2ChlMeOH, 9:1); IR (neat) 1730, 1464,
964, 942 cm- I; IH NMR (400 MHz, CD30D): (major diastereomer)

b

0.84 (t, J=6.8

Hz, 6H), 1.23-1.27 (m, 40H), 1.42-1.47 (m, 4H), 1.96-1.97 (m, 8 H), 2.15 (dd,

J=6.4, 7.2 Hz, 4H), 3.16 (s, 6 H), 3.68-3.71 (m, 4 H), 4.38-4.39 (m, 4 H), 5.27-5.29
(m, 4H), 7.43 ppm (t, J=6.0 Hz, 2H); l3C NMR (100 MHz, CD30D)

b

14.6, 23.9,

27.6, 28.3, 30.4, 30.5, 30.6, 30.8, 31.0, 33.2, 53.3, 64.9, 68.0, 130.9, 131.1, 155.0
ppm; HRMS: m/z [Mt: calcd for C42H82N30/: 660.6401, found: 660.6395.
Zeta potential and Iiposome size measurements
Measurements of liposome size, lipoplex zeta potential and formulated
nanoparticle size were performed using a ZetaPALS dynamic light scattering detector
(Brookhaven Instruments Corporation; Model 90 Plus).

All measurements were

taken in water. Lipoplexes were formulated at a final concentration of 0.1 mg oxime
ether lipid per mL water. To formulate lipoplexes at different N:P ratios, 100 mL of
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the liposome formulation was added to the required quantity of pDNA (taken from a
stock solution of 0.1 mg pDNA per mL) in an Eppendorftube. After incubating each
lipoplex for 15 min, the solutions were diluted to 1 mL by adding ultra-pure water.
Measurements were taken within minutes of formulation.
Liposome formulation
An equimolar amount of DOPE from a stock solution (10 mg DOPE per mL

CHCh) was added to a solution of oxime ether lipid (1 mg) in CHCh (0.20 mL). The
solvent was evaporated, and the resultant thin lipid film was dried under vacuum (4
h). Ultra-pure water (3 mL) was added to the dry lipid film, and the suspension was
sonicated (bath sonicator, Laboratory Supplies Co., Inc., Ithica, NY) for 1 min at RT
to furnish the liposome formulation (0.33 mg oxime ether lipid I mL).
Tissue Culture

Human breast cancer cells (MCF-7) and lung tumor cells (H1792) were
purchased from American Type Culture Collection (Manassas, VA, USA). Cells were
grown to 50-60% contluency prior to transfection. MCF-7 cells were cultured in
Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA), 1%
pennstrep (Mediatech Inc., Manassas, VA, USA, 10% fetal bovine serum (FBS;
Valley Biomedical, Winchester, VA, USA). H1792 cells were cultured in RPMI
(Invitrogen), 1% pennstrep (Mediatech Inc.), 10%FBS.
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Transfection and cytotoxicity studies
Luciferase assay

Luciferase transfections in MCF-7 and H1792 cells were performed in
triplicate using 0.025 mg of pDNA (pCMVLuc) per well. Cells were seeded up to
lX10 5 cells per well in a 24-well plate to give 50-60% confluency, and 400 mL of
media containing 10% FBS was added to each well. Lipoplexes (lipidepDNA
complex) were prepared at N:P charge ratios of 3, 5 and 7 by adding the required
volume of liposome solution to a pDNA solution (3 mL, 0.025 mg DNA per mL) and
incubated for 5 min. Serum free DMEM (100 ilL) was then added to each lipoplex
solution followed by incubation for 20 min at RT with occasional gentle vortex
mixing. The lipoplex solutions were diluted to 600 ilL with serum free DMEM, and
then an aliquot of the final lipoplex formulation (200 ilL) was added directly to each
well. No additional media containing FBS was added to the cells during transfection.
After 18 h incubation at 37.5 DC, the cells were lysed and luciferase expression was
quantified using a commercial kit (Promega Corp., Wisconsin, USA) and
luminometer according to the vendor's protocol. Lipofectamine 2000 (Invitrogen)
and jetPrime (Polyplus Transfection, SA, Illkirch, France) lipoplexes were prepared
at the vendor recommended stoichiometry (2 ilL stock per mg DNA).
Luciferase transfections were also performed in duplicate using 1 Ilg of pDNA
(pCMV-Luc)/well in MCF-7 cells as described above. Cells were seeded up to 4x105
cells/well in a 6-well plate to give 50-60% confluence. Transfection activity of lipid 3
was evaluated at N:P=7. RLU/llg of protein was measured using the BCA protein
assay kit (Bio-Rad, USA).
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GFP expression
Transfection studies were performed using a GFP reporter gene in MCF-7
cells using 0.1 mg of pEGFP DNA (Clontech Laboratories Inc. WI, USA) per well in
a 24-well plate with a similar transfection protocol as described for the luciferase
assays.

Cells were examined 40 h post transfection by fluorescence microscopy

(EVQS, Advanced Microscopy Group, Bothell, WA, USA) and photographed.
Cytotoxicity evaluation
Lipid cytotoxicity was evaluated using the vital dye trypan blue to distinguish
between live and dead cells. MCF-7 and H1792 cells were seeded at 1X104 cells per
well and then grown to 50-60% confluency in 96-well plates. Transfections were
performed as described above. The media was removed 18 h post transfection. Cells
were then trypsinized by adding 100 I-tL trypsin to each well and incubated for 5 min
at 37.5 °C. Trypsin was neutralized by adding IX phosphate-buffered saline (IX
PBS), and then 10 I-tL of extract from each well was mixed with 10 I-tL of trypan blue.
Dead and live cells were counted under an inverted microscope to determine the
percentage cell viability using a hemocytometer.
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6.4. Experimental procedures of Chapter 4
Synthesis

-

o

N,o~~f

OH

OH

OH I \

OMeO

OH

o"foy

Dox·AO

YOH
NH2

2-« (E)-(l-((2R,4S)-4-( «2R,4S,SS,6S)-4-amino-S-hydroxy-6-methyltetrahydro2H-pyran-2-yl)oxy)-2,S,12-trihydroxy-7 -methoxy-6,1I-dioxo-l,2,3,4,6,11hexahydrotetracen-2-yl)-2-hydroxyethylidene)amino)oxy)-N-(2-hydroxyethyl)N,N-dimethylethanaminium iodide (Dox-AO)

To a solution of Dox-HCI (Selleck Chemicals, Houston, TX, USA; 45.0 mg,
0.077 mmol) in anhydrous methanol (35 mL) at room temperature was added N-(2hydroxyethyl)-N,N-dimethyl-2-aminooxyethylamrnonium iodide (2.3, 100 mg, 0.38
mmol) and trifluoroacetic acid (0.5 mL). After stirring the reaction mixture at room
temperature for 96 h, the solvent was removed under reduced pressure. Acetonitrile
(5 mL) was added to the residue and the suspension was sonicated 1 min at room
temperature and then warmed to 40 DC for 5 min. The suspension was then cooled to
-20 DC. After storing 18 h at -20 DC, the supernatant was decanted and the remaining

precipitate (red solid) was dried under reduced pressure to afford Dox-AO (55 mg,
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91%): mp: 50-53°C (dec); IH NMR (700 MHz, CD30D) {) 1.296-1.33 (m, 3 H), 1.92
(dd, J=8.40, 4.20 Hz IH), 2.05 (dd, J=7.7, 3.5 Hz, IH), 2.42 (dd, J=8.4, 6.3 Hz, IH),
2.57 (d, J=I1.2 Hz), 3.15 (d, J=14 Hz, 2H), 3.22-3.32 (m, 10H), 3.36-3.62 (m, 2H),
3.63 (s, IH), 3.72-3-3.86 (m, 3H), 4.03 (d, J=21 Hz, 6H), 4.29-4.30 (m, 2H), 4.514.61 (m, 4H), 4.87-5.04 (m, IH), 5.48 (s, IH), 7.55 (d, J=8.4 Hz, 2H), 7.81 (t, J=7
Hz, 2H), 7.89 (d, J=7.7 Hz, 2H); l3C NMR (150 MHz, CD30D) {) 15.7,28.0, 33.09,
38.1,47.2,47.3,47.4,47.6, 51.8, 54.2, 55.4, 55.8, 63.0, 63.7, 66.4, 66.6, 67.6, 68.5,
71.4, 71.9, 99.6, 110.7, 110.9, 118.9, 119.0, 120.1, 134.9, 135.0, 135.1, 135.9, 154.8,
156.1, 161.0, 162.6, 186,4, 186.8 ppm; HRMS: calculated for: C331-44N3012+ (Mt,
674.2920; found: 674.2926.
Preparation of sNp· AO· Dox

A suspension of Fe304 nanoparticles (5.5 mg) in methanol (1.5 mL) at room
temperature was sonicated (1 min) followed by addition of a solution of N-(2hydroxyethyl)-N,N-dimethyl-2-aminooxyethylammonium iodide (2.3) (30 mg) in
methanol (1.5 mL).

The reaction suspension was sonicated (1 min) at room

temperature and then stirred 12 h. The resultant Np·AO particles were magnetically
sedimented to facilitate removal of the supernatant. The particles then were washed
with methanol (1 mL,2x). The washed particles were dried under reduced pressure
to afford Np·AO (7.42 mg).
A suspension of Np·AO (7.4 mg) in anhydrous DMSO (1.5 mL) at room
temperature was sonicated (1 min).

Within 1 min of sonication, a solution of

doxorubicin-HCI (10 mg) in anhydrous DMSO (1.5 mL) was added. The reaction
suspension then was sonicated (1 min) at room temperature and stirred at room
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temperature an additional 12 h.

The resultant drug-conjugated particles were

magnetically sedimented to facilitate removal of the supernatant. The particles then
were washed with DMSO (1.5 mL, Ix).
centrifuged for 10 min at 4

0c.

The supernatant was collected and

The pelleted and magnetically separated partcicles

were combined and dried under reduced pressure to afford sNp·AO·Dox (9 mg).
Synthesis of dNp·AO·Dox
Fe304 nanoparticles (NP, 7 mg) were suspended in anhydrous DMSO (1.5
mL) at room temperature and sonicated (1 min, room temperature) using an Ultra
Sonicator water bath. To the resultant NP suspension, a solution of Dox·AO (20 mg)
in anhydrous DMSO (1.5 mL) was added.

The reaction suspension was further

sonicated for 1 min at room temperature and then stirred 12 h. The resultant drugloaded particles were purified as described above to afford dNp·AO·Dox (9.4 mg).
Synthesis of Np·Dox
A suspension of Fe304 nanoparticles (9.0 mg) in anhydrous DMSO (1.5 mL)
at room temperature was sonicated (1 min) followed by addition of a solution of
Dox·HCI (20 mg) in anhydrous DMSO (1.5 mL).

This reaction suspension was

sonicated (1 min) and then stirred at room temperature for 12h. The loaded particles
were isolated using the magnetic separation and washing procedure described above
to furnish NP·Dox (10 mg).
NP characterization
Transmission electron micrograph of dNp·AO·Dox
Methanol suspensions of dNp·AO·Dox samples were deposited on
transmission electron microscopy (TEM) Cu grids coated with a carbon film. TEM
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microstructures and energy dispersive X-ray (EDX) spectra then were measured using
a JEOL JEM 3200FS at 300 kV equipped with an EDX detector. TEM measurements
were performed at the Indiana University (Bloomington), TEM facility.

Dox-AO loading calculation
Volume of 1 mg NP = mass/density = 0.001 (g)/5.24 gcm-3 = 0.0002 cm 3 (V)
Volume of one NP = 4/3

1tf3

= 5.23XlO- 19 cm3 (VI)

Number ofNPs in 1 mg = V/ VI = 3.82X1014 (X)
0.37

~mol

Dox-AO is attached! mg NP

Number of Dox-AO molecules in 0.37 ~mol = 2.22XlO17 (XI)
So, number of Dox-AO molecules attached to each NP = Xt/X = 580
Surface area of a single NP = 4 1t~ = 31428.57 A2 (A)
Polar surface area (PSA) of 4.1

= 21 A2 (PSA was calculated using a

software form

http://www.daylight.com/meetings/emugOO/Ertlltpsa.html)
So, maximum number of Dox-AO molecules that can attach on surface side by side
of each NP or footprint of Dox-AO = NPSA = 1450

Zeta potential measurements
The zeta potentials of NP, sNP-AO-Dox, sNP-AO-Dox, NP-Dox were
measured in IX PBS using a ZetaPALS dynamic light scattering detector
(Brookhaven Instruments Corporation; Model 90 Plus). The concentration of each of
the sample was 0.3 mg NP/mL buffer.

AMF -induced NP heating
A suspension of dNP-AO-Dox (2.5 mg) in PBS (1 mL) was exposed to a
continuous AMF (EASYHEAT'M 8310LI solid state induction power supply,
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Ameritherm, Inc., 5 turn coil with ID: 5.0 cm and OD: 6.5 cm, 203 kHz, 350 A) for
18 min. The AMF exposure was started after the temperature of the suspension had
reached 37.0 °C. The temperature of the suspension was measured every 3 min using
an optical fiber temperature probe (Neoptix Inc., Quebec, Canada).
Solution containing AMF-triggered drug was analyzed by HRMS.

The

supernatant was collected after AMF exposure and diluted to 0.5 !!mol for analysis
using

a FT-ICR-MS

(Fourier Transform Ion Cyclotron Resonance

Mass

Spectrometry ).
Drug release studies
AMF -induced drug release
The drug-loaded nanoparticle formulation were suspended in PBS by
sonication (1 min) and then subjected to AMF-exposoure (203 KHz) for 18 min.
Every 3 min, a 10 !!L of aliquot was taken out and diluted to 1 mL for UV
measurements at 480 nm. 86, The concentration of drug released was calculated using
Beer-Lambert's law. Release study was performed in triplicate.
According to Beer Lambert's law: A = dc
Where, A is the absorbance;

£

is the molar absorptivity (a constant); I is path length (1

cm). Thus, if the path length and the molar absorptivity are known and the absorbance
is measured, the concentration of the substance or 'c' can be deduced.
Drug release study at 37.5 °c
dNp·AO·Dox (3 mg NP/mL in PBS) was incubated at 37.5 °C for 18 min.
Drug release study was conducted in similar fashion as stated above.
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AMF -induced drug cytotoxicity in MCF-7 cells

Human breast cancer cells (MCF-7) were purchased from American Type
Culture Collection (VA, USA). Cells were plated in 30 mm dishes at -4X10 5
cells/dish, and then grown up to 50-60% confluency in DMEM, 1% Pennstrep
(Mediatech, Inc, VA) and 10% FBS (Valley Biomedical, Winchester, VA).
Stock solutions of the nanopartic1e formulations NP·AO, dNP·AO·Dox,
sNP·AO·Dox, and NP·Dox, were prepared in PBS IX buffer solution at a uniform

Fe304 concentration of 1 mg/mL. To the MCF-7 cells maintained at 37.5 DC were
added specific doses (0.1, 0.25 mg or 0.5 mg) of the NP formulations. The required
volume of NP formulation was first diluted to 2 mL in DMEM containing 10% FBS.
The media was removed and NP formulations were added to the cells. After 1 h of
incubation with NP formulation at 37 DC, cells were exposed to a continuous AMF
for 15 min using same parameters as described above. Dox·HCI (0.5 !-lmol) and
Dox·AO (0.5 !-lmol) served as positive controls.

added) cells were also exposed to an AMF.

Untreated (no NP formulation

Cells were also treated with NP

formulations but not exposed to an AMF; these served as another control group for
the experiment. After AMF exposure, the cells were incubated at 37.5 DC for 48 h.
The media was then removed and the cells were trypsinized by adding 500 !-lL trypsin
to each well and incubated for 5 min at 37.5 DC. Trypsin was neutralized by DMEM
containing 10% FBS, and then 10 !-lL of extract from each well was mixed with 10
!-lL of trypan blue. Dead and live cells were counted under an inverted microscope to
determine the percentage cell viability using a hemocytometer.
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Fluorescence imaging of MCF-7 cells

A cytotoxicity experiment was performed exactly as described above on
MCF -cells using the NP drug formulations.

After 6 h of treatment media was

removed and 1 ml of IX-PBS was added to each dish. Then fluorescence images of
cells were taken using a fluorescence microscopy (ex/em: 480/590 nm, EVOS,
Advance Microscopy Group, WA).
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APPENDIX A

A.1. Index of NMR Spectrums and Other Figures
A.2. NMR Spectra and Other Figures Obtained in Chapters
2,3, and 4
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A.I. Index ofNMR Spectra and Other Figures
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Dox·AO
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Dox·HCl and Dox·AO
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NPs

Microscopy images of MCF-7 cells treated
with formulations
TEM micrograph

NPs

EDX spectra
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dNP·AO·Dox
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Figure A.L Microscope images of MCF -7 cells after 48 h of treatment with Dox and
Dox·AO . A. Untreated cells. B. Dox·HCl treatment. C. Cells treated with Dox·AO.
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Figure A.2. TEM micrograph of Fe304 nanoparticles.
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Figure A.3. EDX sptectrum ofNPs.
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20

Figure B.4. TEM micrograph of dNp· AO· Dox particles; inset is a single particle.
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list summarizes the publications that arose from my research and the Chapter(s) in
which the work is described more fully. Also attached are the title pages of these
works in the section B.2.
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Biswas, S.; Gordon, L. E.; Clark, G. J.; Nantz, M. H. Click Assembly of
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Biswas, S. ; Knipp, R. J; Gordon, L. E.; Nandula, S. R; Gorr, S.-U; Clark, G. 1.;
Nantz, M. H. Hydrophobic Oxime Ethers: A Versatile Class of pDNA and siRNA
Transfection Lipids. ChemMedChem 2011, 6, 2063-2069. [Chapter 3]
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Fu, X-A; Li, M; Biswas, S; Nantz, M. H.; Higashi, R. A. A Novel
Preconcentration Approach for Analysis of Ketones and Aldehydes in Breath.
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Li, M; Biswas, S; Nantz, M. H.; Higashi, R. A.; Fu, X-A. A Novel Nethod for
Detection of Ultra Trace Ketones and Aldehydes. Analytical Chemistry 2011, In
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Biswas, S. ; Gordon, L. E.; Clark, G. J.; Nantz, M. H. Externally Directed AMFtriggered Release of Doxorubicin from Magnetic Carriers. Nano Letters 2011,
manuscript in preparation. [Chapter 4]
7.
Wang, 1.; O'Toole, M. G. ; Massey, A. P.; Biswas, S.; Nantz, M. H. ; Achilefu, S.
and Kang, K. A. Highly Specific, NIR Fluorescent Contrast Agent with Emission
Controlled by Gold Nanoparticles. Advances in Experimental Medicine and Biology
2011 , 701 , 149-154. [this research, a side project, is not detailed in this thesis]
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ABSTRA CT

Nurloqitilic atioriution reapnts fk1rd with ominooxy groups an! describl!d. I'ra<tfcal synthesrs ci
mono- and bis-arrinooxy tolTa..Ikylammanium iodid!s indJding N-h~mcyahyl.functionalilled analogs
ar"repoltl!Ci An oximation .,.omp!! usill! on" lith" ~agents is pr4!S4!nt4!d to illustr.lt"thtir US" in synthl!Sis ci cationic matHials.
C 2010 ElSI!Vier Ltd. All rights 1'4!$4!IV4!d.

A wide V.1fiety Ii materials have been modllied by the covalent
.1tuchment of quaternary .1mmonlum fullCtlonallly to furnish
derlvatlves with overall positive c:harge. ' This proce;s, a derlvatlzatlon known as catlon~t1on. typical Iy procted$ via reaction of the
substra~ with an electrophlllc reagent oontllnlng.1 quaternary
ammonium salt Fa: eumple. the catloniLltion of prold1l$ ls performed toenllance their lntracdlul.tr deUvery via adsorptJv~med
lated endocytosis. 2 The catIonizatlon cl cellulose fibers (e~
cotton) can Improve the upuk:e of dyes In subsequent coIa:lng
operations. 3 These applications and others principally reJy on catloniLltlon re.1ll'!nts of the type 1- 5 depicted In Figure 1. Indeed.
chiorohydrln ' · .tnd epoxide re.1ll'!nts 25 and 3" holve been partieuLtrly useful for the cationiLltion of wboh)'drate domalns In reolCtIons with bases at elevated temperatures. The reagents 47 and SIDustrate other permutations cl reactive electrophiOc groups used
In reactions to derlvatlze materLtls with ammoolum salts.
Of particuLtr Interest 10 us" ls the use cl quaternary ammonium
salts attached to lipid- a: polymer-frameworks as vehicles for the
IntraceDuI.1r delivery of polynucleotldes to mammalLtn ceJls.'·
We felt that a mlk\, more convenient procedure for direct attachment of .1mmonlum Ions to substrates v.ouJd greatly Improve
our .1bDltles toacress 11M cationic materials. On considering alternative Slrateg:ies. the chernospedlic reaction between amlnooxy
and kttone or .1ldehyde carbonyl groups appeared to be an ldea~
nucleophlOc counterp.ut to current method$.' 1 Given the ease of
oxlrnatlon and the rd>ust nature of the CIlClrne ether linage. we
targeted amlnooxy re.1ll'!nts 6.1 and 6.2 (FI~ 2) fo r synthesis. OUr
Interest In gene transfer ma~rl.als also led us to prep.tre hydroxyethyl·funct\onallz.ed an.1\ogs 7.' and 7.2. Thebenefitofh)<dracy~
thylated pow domains In gene delivery Is ~II documented. 12
Consequently, we disclose herein a genera l synthesis of the novel
nucleophilic catlonlzatlon re.1gents 6 and 7.

• CDtRSp<II4l11u har. Toi~ <1502 1152 1IIIi!I: lllC . 1502 85Z 7214.
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Old
loci
~

M.lFe

." IJI ... ICY «I2!Il. 1.54
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with ~ nmonilm ion-bued aminOOltY <U1d
IItxibie IOltefar ner~tinlllli1Jl1t1lc~eddmyverlO".Usirc the
MCF-7 brustall,:l!fcrllline,wrfinclnJS $/tow that pO/lll\ f'NII1r!IDpI~deriwd fiorn the lipid-coated
~de rorrnula.tion dMLP I11llUl'ea In me plt!$tllte of lOS smun with or wimout RU&naic
usUtante t slIrillcandy hiJher levels man .. ammonly II$ed ationic Ilposome forrllJlatian, bad on
uclerue lISSi)l. The present ion~iril" dlc:lc chemistry .tPProach fumi.shes reA n.nopal1klts with
ipid ..yas. The ~ltant rn &netic nanoYA!ttOrs 2IW lIS trmsfectian enhancers for otherwise transfecdon-ln.ttaive RUtm.

axirneethefSubstr~

IIln~de:s

provIdes~

(II

M.I.,e~a

I . Inrroducdon

Since the mlna! report by Mah's group on the useot m~dc
n.1llopartlcles to enh.mce v\raJ...m~tfXI transduc:tlon III. much
rese.uch effort has been dlreClrd toward the development d nanoslud RUgJletlc vectors fot Intt~lIUW'deUvery or polynudeotldes
(21. Indeed, the rising ntere In 'lNgnetoli!ct!on'. the ~rm mlnfXI
by Scherer etaL(31 to denote magnet sistfXI ~ne delivery [4.51.
has IfXI toa plethora of new trategles for funct\on.tlill .magnetlc
particles to ptomo~ assocImon with neptJvely dlarged 011 onudeotlde$ [6L DNA or siRNA (71. The m*dty of apprG.llches have
relied on co.Kl Iron oxide n.tnopartlcles Of O.1IIOCDroposl s with
atlo
polymer$. such as pol}"4.~Iy$lne 181 or. In p~ttlcuLu po
et!\ylen mine (pa ) I 11 ~ The high poslti¥e cha~ (121 of PEl
eff«tl ely promo~s DNA transfer InlO cells. AddItIon.tlly. the
polyamine b.lckbone of pa enhances esape of DNA co~lexes
entrapped within endosomes by me
d a prolOn po e effect
that: incrt.lses osmotic pressure ~nd causes endosome rupture 1131.
M~gnetlc PEJ..cN~d n.1llopartJcles ~nerilly
pre:parfXI by
mixing suspensions of m nedte (FoOt) nanocrysui.s with sotutIons of linear or bf.1llched PEl (141. More recently. ;an In sltu
pre:pa~lon IISI InwIvIng predpl~n of Lton CIt/de In Ihe presence of PEl ~nd ~ method for covalent attachment (161 of PEl to
chltosan-coated Iron 0 Ide O.1IIopardcles have been de bed
Elaboration of PEj..<n.l~d lton oxIde nanopartlcles. such as by

ftC:

0l4208612/S -

a II1II«. ~l! 1 SOl 1152 ICIi!J..
mk:bIoLaana....
(MJf. HIIIID).

addition of atlon peptide fragments (171 0 single chain antibodies 1181. ls also.In .tee. under Intense In...estlgatlon.lrrespectlve
of the mode of genentlon or Subsequent funcdonaJludon.
magnedc PEkoatfXIlron CIOde n.tnovectors readily ClImb ne with
polyoocleotlde$ on Imple mixing to ~nerate the correspond!
m~dc electrostatic cha~-.llftnlty oo~lexes. The te:sul
'magnetoplexes' (nomenclature derived by extrapolation of Ihe
established ~rm magner:oliposome (191 ~nd the terms Iipoplex .. nd
polyplex [20D have beenusedprl palJy for gene delivery n tro;
ha.ve...er. successful RUgJlaofe<tlon also h.lS been demonstratfXI n
~IW) by ex~1'N11y applying a m netic gradient to the treatment
area. for t!lWIlple (211.
Ihe
One concern that plagues appliatlons Inwlvlng PH
~ssoc\ated cellular tCltlcity. The high positive char~ den ty of PEl
disrupts
u1ar merrbranes (221: thus, complications a ng ftom
vector toxicity alllict many PEl-based gene Ihmpy approaches
1231. To overcome th limitation, ~ teO!nt focus I the l'ield of
~netorectlon has been to de...elop IJpicI-ba d magnecoplexes.
This strategy has been realized In part by mild preformed II
oplexes (C.ttIonic I pld:helper Iipld:ONA)wlth m netill! (241 or by
.adding tr.ans fe(tlon-actlve a lion Ic llposome for mulations (C.ttIonlc
IIpld:helper lipid) to either oleic ackk:oatfXI l25261 or dextr.a,..
coatfXI l271 mapetlte prior to complexation with nucleic adds to
form ma,gnetoplexes.
Given thOlt the molecular structure d atlonlc lpid.s his
.I prdound Inlluence on ~ne delivery (28). Itls surprlsl 1h0lt bY
m nelOfectlon srudles have exploited struClUre-actMty optlmj..
utionsofli!rfXI bya modular. I pld-b.lSed approach. OUr prognm on

fmnr INIU!r 0201 1 Ekev1!r lid. All 11"," ",.rwd.
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DOl: 10.1002/andc.201100259

Hydrophobic Oxime Ethers : A Versatile Class of pONA and
siRNA Transfection Lipids
Souvik Biswas}a] Ralph J. Knipp/a] Laura E. Gordon/b] Seshagiri R. Nandula,lcJ Sven-Ulrik Gorr,[e)
Geoffrey J. Clark,iJl] and Michael H. Nantz*la]

The manipulation of the cationic lipid structures to lnaease
polynucleotide binding and delvery properties. wille also mininlzlng assod.eeI cytotollid~ has been a principal Slrategy
for developing next-generation transfection agents. The polar
(DNA binding) and hydrophobic domai15 of transfecdon Ipids
have been extensiYely stucled; howeYer, the linking domain
comprising the substructuJe used to tether the polar and hydIophobic domains has attracted considerably less attention as
an opd milatIon variable. Here. we examine the use of an
olIime ether as the Inking domain. Hydrophobic olIime ethers
Wl!Je rNdIy assembled via dick chemistry by ollimatlon of hy-

drophoblc aldehydes using an amInooxy salt. A facie IgatJon
reaction delivered the desked compounds with hydrophobic
domain asymrneuy. umg the MCf-7 breast cancer. H1792
lung cancer and PAR C10 salivary epI1helal eel Illes. our find.
Ings show that IpopIell!5 derived from oxime ether lipids
transfect In the presence of serum at higher levels than c0mmonly used lposome formulations. based on both Iuclerase
and green fluorescent protein (GFP) assays. GIven the bIoI~
cal mmpatiblity of ollime ethers and their ease of fonnation.
this func1IonaI group should tlnd significant applcatlon as a
Inking domain In future designs of transfectlon vectors.

Introduction
Cationic lipids and their derived liposomes have become the
most well-studied and widely used synthetic. nonviral gene delivery vehicles since Feigner et al lli first disclosed DOTMAmediated gene transfer in 1987.12.1I Due to the major fimitations of viral vectors, such as associated Immune responses,
limited polynucleotide carrying capacity and high cost.lI.~ cationic fipids remain an attractive alternative. The advantages of
low Immunogenicity. the ability to transfect RNA or DNA of
nearly unlimited size.'" '' and the relative ease of cationic lipidplasmid DNA (pDNA) or RNA complex (lipoplex) formulation- ]
continue to attract interest aimed at developing saler and
more efficient cationic lipids for use as transfection agents.1I1
Cationic lipid molecules. such as the prototypical dual chain
lipids DOTMA" ] and OOTAplO1 (Figure I). contain a polar. positively charged (DNA binding) head group connected to a hydrophobic domain via a linking functionality. These three principal structural components of cationic glycerol-type lipids

have been extensively studied in efforts to improve lipid-mediated intraceHuiar delivery of polynucleotides to mammalian
cells.I" 1 Many structure-activity relationships have been determined. >. Ill particularly for the hydrophobic domain. Indeed.
the hydrophobic domain's structural variables of chain length.
degree of unsaturation. and domain asymmetry are among the
strongest contributors to transfection efficaCY, 4 Fewer direct
structural comparisons of changes in the cationic lipid backbone. or linking domain. have been reported. with the most
weU-Itnown comparison being that of the diether DOTMA
versus the diester DOTAP.o" The linking functionality. and to a
lesser extent the cationic head group. seem to be the prinCipal
determinants of toxicity. H71 The linker determines conformational flexibility. degree of stabiUt)4 and biodegradability.
Among the most studied chemical functionalities comprising
the linking domain of transfection fipids are the ether. ester.
ortho ester,' .....1 carbamate. I amide."ll'l and phosphonol2~
moieties.
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fig .... 1. Struetl.nl cIomains of oommon transfe<:tion lipids.
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A novel microreactor approach for analysis of ketones and aldehydes in breath
Xiao-An Fu, *11 Millgxiao L~a ouvik Biswas/ Michael H. Nalltzb iUld Richard M. Higdshibcd
Rt!rei.ed 1911r July lOll, Accepled 1911r AuguSI101 J
001: IO.I039/c1anl56ISg

We report a fabricated microreactor with thousaols of micJ'opilars
in channels. Each micropillar surface is chemically functiooalized 10
selecti~e1y precoocentrate gaseous ketones and aldehydes of exhaled
breatb and to enbanre ultra-trace, rapid analysis by direct-infusioo
Foorier transform-ioo cyclotron reliOllWlCe (FT-ICR) mas spec.trometry (MS). The mlcropillar reactive coating contains the
quaternary 3mmoniwn amioooxy salt 2-(amioooxy)ethyJ- ,N,Ntrimethyl3JUlllOlli1Dll iodide (ATM) fc. capturmg trace carbon)i
VOCs by means of 30 oximatioo reaction. We demonstrnle the
utility of this approach for detection of C. to CIl aldehydes and
ketones io exhaled breath, but the approach i a wicable to any
gaseous sample.

Aoalysis of exhaled breath has been elevated to an international
research frontier because of its potential and applicabitity in noninvasive reaJth diagnosis, metabolite bioinformata, and drug
discovery.... The gISCOOS portion of breath is a oomplex mixture of
atmospheric gases, water vapor. and trace volat~e ol"!1ilnic
compounds (V0Cs). In 1m, Pauling reported the first ~ro
matographi.: analysis of !reath, and the study revealcxl the preserx:e
of a larg: number of VOCs in human !reath.' A nIDDber of recent
pUbtications suggest that the analysis of exhaled breath promises to
be a non-invasive diagnosis for early detection of particulate cancers
since some VOCs in exbaIcxI breath represent metaboli.: output of
cancer tissues and ceOs.'-u
There are se\\:ra1 criticaJ challenges for the analysis of VOCS in
exhaled breath, including u1tra-trace concentrations of VOCs and
interference of complex gas mixtures. Exhaled breath contains more
than 200 VOCS. Recently, several reports indimte that some ketones
and aldehydes in exhaled b-eath coukJ be used for the diagnosis of
IWJg cancer in its early stag:.....' ....u
However, so far there is no estabtished protocol for the analysis ofaD
ketones or akJehydes in exbaJod breath. in part due to their highly
reactl\\: nature. These carbonyl metabolites are produccxl in
biochemical pathways as intermediates and some can be WJique to
"Department of o,emiCQ! Engintrring, University of Louisville, Louisville,
K y, «J208, USA. E-maiL' xiooon.fit@1ollivU!udu
'Department of Chemistry. Uni~rsity of LouisvUIe, LouisviJl~ KY, «J292,
USA
<Cemer for Regulatory and Environmental Analytical MetaiJolomic;s
( CREAM), University of LorosviUc, LOllisvin•• KY. 40208. USA
'Jomes Graham Brown ClIneer Centtr. Uni~rsity of Lorosl'ilJe, Lord.rville,
KY, «J292
4662
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a given pathway or process. However. e\'en common carbonyl
metabolites can be attributed to specific processes when stable isotope
labeled substrates are metabolized (e.g. by hIDDan subjeas) and
detected by mass spectrometry or NMR.'4,U Volatile ketones and
aldehydes are also genemted from damaging oxidatiyc reactions, such
as lipid peroxidation.' .... Thcrcfore, developnent ofa new method for
analysis of ketone and akJehyde VOO in exhaled breath is a (J1lcial
first step to fulfilling the potential that breath analysis promises.
Ketones and aldehydes can be detected by proton transfer reaction
mass spedromctry (PfR-MS),....... or selected ion ftow tube mass
spectrometry (SlFT-MS) without any preconcentration process.2WS
Most recently. solid phase mi.:roextractlon (SPME) with adsorbed
0-2.3,4,s.6-(pentalluorobenzyl)bydroxylamine
hydrochloride
(PFBHA) has been used for analysis of akJehydes in exhaled breath
by gas cbromatography-mass spedrometry (GC-MS).· .. SPME is
a popular preconcentration method introdwed a decade ago as
a mpid extraction technique for analysis of volatile compoWJds from
a variety of matrioes?~ However, tbe surface area of the SPME
polymer extractlon phase is smaD and akJehyde capture requires
physical adsorpt.ion of PFBHA onto SPME first. In most cases, it is
also extremely difficult to improve upon, or even determine the
volIDDe of air that is actuaDy samploo by the SPME fiber. The quality
of the fibers depends on the manufacturer, and the perfonnance
varies from batch to batch. Derivatilation of ketones and akJehydes
by reactlon with 2,4-dinilrophenylb)drazine has aro been used for
analysis of carbonyl compounds in exhaled breath, ..." which has the
advantage of converting volatile aldehydes and ketones into stable,
easy.to-bandle non-volaille anaIytes. Howe\I:l", this dass of reagents
was not designed to aid in detection by modern ultra-sensitive MS ion
sources such as nanoelectroopray.
In this work, we deuibe a muoreactor approach for chemoselective capture of ~us ketones and akJehydes from gaseous
samples uch as exhaled breath. The microreactor was fabricated on
a ~icon wafer and charged with an aminooxy-/imctlonalized
quaternary ammonium sail The high selectivity of the aminooxy
moiety (R-ONHz) for reaction with ketone and aldeh)de carbonyl
groups suggested tbat an oximation reaction coukJ be used to seJecti'!:ly capture ketone and aldehyde metabolites dirertly from the air.
such as exhaled breath. For rapid analysis and identification of VOC
addtds, we additionally turned to direct-infusion nanoelectrospmy
FT-Iffi-MS analysis. This muoscale sampling to:bnique matcbcxl
the samples sizes of the mi.:roreactor, and the u1tra-high resolution
FT-Iffi-MS enables simultaneous analysis of the ketone and aIdebyde addu:ts, while avoiding analytical interference from the capture
Thi5 journal is
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A Novel Method for Preconcentration and Analysis of Trace
Volatile Carbonyl Compounds
Mingxiao Lia, Souvik Biswasb, Michael H. Nantzb,
Richard M. Higashib,c, Xiao-An Fu*a
Departments of 'Chemical Engineering and 2Chemistry, 3Center for Regulatory and
Environmental Analytical Metabolomics (CREAM), and

4

James Graham Brown

Cancer Center, University of Louisville, Louisville, Kentucky 40292

ABSTRACT:

This paper demonstrates a novel preconcentration approach for

quantitative analysis of trace volatile ketones and aldehydes in air and in human
breath. The approach is based on the fabricated microreactor chips on a silicon wafer.
The microreactors have thousands of micropillars in the microfluidic channel for
uniformly distributing gaseous sample flowing through the microreactors.

The

surfaces of the micropillars are functionalized with a quaternary ammonium
aminooxy 2-(aminooxy)ethyl-N,N,N-trimethylammonium iodide (ATM) synthesized
in-house for trapping trace ketones and aldehydes by means of an oximation reaction.
The ATM adduct and unreacted ATM can be easily eluted from the microreactor with
less than 40 microliter of methanol and directly analyzed by nanospray Fourier
transform-ion cyclotron resonance (FT-ICR) mass spectrometry (MS). Ketones and
aldehydes in a concentration of 1ppbv can be detected. The microreactor approach is
suitable for quantitative analysis of ketones and aldehydes in exhaled breath.
KEYWORDS: Preconcentration, Microreactor, Breath Analysis, Ketones, Aldehydes
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Chapter 21

Highly Specific, NIR Fluorescent Contrast Agent
with Emission Controlled by Gold Nanoparticle
Jianting Wang, Martin O'Toole, Archna Massey, Souvik Biswas, Michael Nantz,
Samuel Achilefu, and Kyung A. Kang

Abstract Nanoparticles are currently being intensively studied for in vivo molecular
imaging because of their unique and beneficial properties. Among these particles,
some metal particles possess strong surface plasmon fields that can effectively alter
fluorescence. Using this fluorescence alteration, an NIR fluorophore based, nanosized contrast agent for breast cancer diagnosis is being developed. The fluorophore is
conjugated to gold nanoparticles (GNP) via a short spacer whose length was specially
adjusted to have the strong plasmon field to quench the fluorescence. The spacer also
has a special molecular sequence that can be cleaved by an enzyme secreted by
targeted cancer cells. Normally, the entity does not fluoresce. If it is delivered to the
cancer site, the short spacer would be cleaved by the enzyme secreted by the cancer
cell at which point the fluorescence would be restored. This entity can incorporate
a cancer targeting molecule for a cancer specific delivery. The entity specifically
targets cancer cells and fluoresce only when the spacer is cleaved by a specific
cancer secreting biomolecule, providing dual specificity for cancer diagnosis. In the
future, this entity will be combined with cancer drugs for seamless detection and
personalized therapy.

21.1 Introduction
Fluorescence contrast agents have been extensively used in clinical diagnosis. Naturally, the agents providing high specificity are highly desirable for molecular imaging. Recently, nanoparticles have been intensively studied as candidates for image
contrast agents and drug delivery because their small size allows interactions with
Jianling Wang, Martin O'Toole, and Kyung A. Knng
Department of Chemical Engineering, University of Louisville, Louisville, KY 40292, USA
e--mail: kyung.kang@louisville.edu
Archna Massey, Souvik Biswas, and Michael Nantz
Department of Chemistry. University of Louisville, Louisville, KY 40292, USA
Samuel Achilefu
Department of Radiology, Washington University School of Medicine, St. Louis, MO 63110, USA
Ie. LaManna et ai. (eels.), Ox)gmr Transport to TISsue XXXII, Advances in Experimental
Medicine and Biology 701,00110.10071978-1-4419-7756-4_21,
e Springer Science+Business Media, lLC 2011
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